IGF2BP1 induces high-risk neuroblastoma and forms a druggable feedforward loop with MYCN promoting 17q oncogene expression

Sven Hagemann[1,*], Danny Misiak[1], Jessica L. Bell[1], Tommy Fuchs[1], Marcell I. Lederer[1], Nadine Bley[1],

Monika Hämmerle[2], Ehab Ghazy[3], Wolfgang Sippl[3], Johannes H. Schulte[4,5], Stefan Hüttelmaier[1,*]

[1] Institute of Molecular Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany

[2] Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle, Germany

[3] Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle, Germany

[4] Department of Pediatric Oncology and Hematology, Charité–Universitätsmedizin Berlin, Berlin, Germany

[5] German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany

[*] shared correspondence authorship: Stefan Hüttelmaier (Stefan.huettelmaier@medizin.uni-halle.de), Sven Hagemann (sven.hagemann@medizin.uni-halle.de)

Abstract

Background: Neuroblastoma is the most common solid tumor in infants accounting for approximately 15% of all cancer-related deaths. Over 50% of high-risk neuroblastoma relapse, emphasizing the need of novel drug targets and therapeutic strategies. In neuroblastoma, chromosomal gains at chromosome 17q, including *IGF2BP1*, and *MYCN* amplification at chromosome 2p are associated with adverse outcome. Recent, pre-clinical evidence indicates the feasibility of direct and indirect targeting of IGF2BP1 and MYCN in cancer treatment.

Methods: Candidate oncogenes on 17q were identified by profiling the transcriptomic/genomic landscape of 100 human neuroblastoma samples and public gene essentiality data. Molecular mechanisms and gene expression profiles underlying the oncogenic and therapeutic target potential of the 17q oncogene *IGF2BP1* and its cross-talk with *MYCN* were characterized and validated in human neuroblastoma cells, xenografts and PDX as well as novel IGF2BP1/MYCN transgene mouse models.

Results: We reveal a novel, druggable feedforward loop of IGF2BP1 (17q) and MYCN (2p) in high-risk neuroblastoma. This promotes 2p/17q chromosomal gains and unleashes an oncogene storm resulting in fostered expression of 17q oncogenes like BIRC5 (survivin). Conditional, sympatho-adrenal transgene expression of IGF2BP1 induces neuroblastoma at a 100% incidence. IGF2BP1-driven malignancies are reminiscent to human high-risk neuroblastoma, including 2p/17q-syntenic chromosomal gains and upregulation of Mycn, Birc5, as well as key neuroblastoma circuit factors like Phox2b. Co-expression of IGF2BP1/MYCN reduces disease latency and survival probability by fostering oncogene expression. Combined inhibition of IGF2BP1 by BTYNB, MYCN by BRD inhibitors or BIRC5 by YM-155 is beneficial *in vitro* and, for BTYNB, also *in vivo*.

Conclusion: We reveal a novel, druggable neuroblastoma oncogene circuit settling on strong, transcriptional/post-transcriptional synergy of MYCN and IGF2BP1. MYCN/IGF2BP1 feed-forward regulation promotes an oncogene storm harboring high therapeutic potential for combined, targeted inhibition of IGF2BP1, MYCN expression and MYCN/IGF2BP1-effectors like BIRC5.

Keywords: 17q gain, BIRC5 (survivin), BTYNB, IGF2BP1, Mivebresib, MYCN, neuroblastoma, PDX, RNA-binding protein (RBP), transgenic mouse model, YM-155

Background

Neuroblastoma is the most common extracranial childhood tumor and originates from precursors of the sympatho-adrenal cell lineage [1]. High-risk neuroblastoma (HRN) accounts for approximately 15% of all cancer-related death in infants and despite intensive multimodal therapy >50% of HRN relapse [2]. This emphasizes the need to elucidate novel drug targets and therapeutic avenues. Neuroblastoma is commonly associated with genomic abnormalities including *MYCN* amplification (~25-35%; Chr 2p), 1p and 11q loss as well as 17q gain, the most frequent (>50%) chromosomal aberration [1-4]. Intriguingly, 17q gain is frequently associated with *MYCN* amplification and adverse disease outcome, but genetic synergies of 2p and 17q remain largely unknown [4]. Candidate oncogenes at 17q are suggested by the fact that gains at 17q are recurrent events also in other cancers, e.g. breast cancer [5] or medulloblastoma [6], and high passage human embryonic stem cells (hESCs) [7]. Two main issues have restricted the use of 17q gain in cancer management, a robust cut-off criterion for gains and only few confirmed and druggable 17q target genes. However, several studies identified 17q oncogene candidates, including *TBX2*, *PPM1D*, *TOP2A*, *BIRC5* and *ALYREF* [8-13]. Another 17q gained candidate gene, *IGF2BP1*, was reported to associate with poor neuroblastoma outcome [14, 15]. The insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an oncofetal RNA-binding protein with reported gene gain and suggested MYCN-associated roles in neuroblastoma [14]. The main function of IGF2BP1 in cancer is the partially m^6A- (N^6-methyladenosine), but typically microRNA- (miRNA) and 3'UTR-dependent stabilization of mRNAs [16-21]. This results in elevated expression of oncogenic factors like LIN28B, MYC and E2F1 [22-24]. IGF2BP1 is upregulated in higher-risk clinical neuroblastoma groupings, including *MYCN*-amplified (MNA) or INSS-4 (International Neuroblastoma Staging System) tumors [14]. IGF2BP1 is *de novo* expressed in several cancers and shows conserved association with poor prognosis, disease progression and metastasis [21]. However, it remains unknown if IGF2BP1 is an oncogene in human

cancers, how it synergizes with MYCN in neuroblastoma, and if the targeting of IGF2BP1 harbors therapeutic benefits in cancer treatment.

Here, we reveal that IGF2BP1 is a *bona fide* druggable oncogene in neuroblastoma. For the first time, we demonstrate, that sympatho-adrenal transgene expression of IGF2BP1 is sufficient to induce HRN characterized by 2p/17q-syntenic chromosomal gains and upregulation of Mycn. MYCN and IGF2BP1 synergize by transcriptional/post-transcriptional feedforward regulation, which unleashes an oncogene storm, including upregulation of 17q genes like BIRC5/Birc5. In neuroblastoma cell and xenograft models, IGF2BP1 deletion and inhibition by the small molecule BTYNB [25] impair tumor growth. BTYNB robustly disrupts MYCN/IGF2BP1 synergy, downregulates 17q oncogenes and is beneficial with both, BIRC5 inhibition via YM-155 [26] and MYCN inhibition by the BRD-inhibitor Mivebresib [27].

Methods

RNA-seq library preparation and sequencing. Library preparation of human neuroblastoma tumor samples was performed on fragmented RNA. A pool of up to 10 libraries was used for cluster generation at a concentration of 10 nM using an Illumina cBot. High-throughput sequencing of 100 bp long unstranded paired-end reads was performed with an Illumina HiScanSQ sequencer at the sequencing core facility of the IZKF (Leipzig) using version 3 chemistry and flowcell according to the instructions of the manufacturer. For RNA-seq library preparation of transgenic mouse tumor samples, 2 µg of total RNA served as input for polyA(+)-RNA enriched and strand-specific library preparation, performed by Novogene (Hong Kong). Sequencing was accomplished with an Illumina NovaSeq 6000 machine.

Shallow whole genome sequencing. A total amount of 50 ng - 1 µg DNA per sample was used as input material for DNA sample preparation of human neuroblastoma and transgenic mouse tumor samples. Shallow WGS (sWGS) of all samples was performed on an Illumina NovaSeq 6000 at Novogene (Hong Kong), resulting in a low coverage of around 0.7x per sample.

Analysis of high-throughput sequencing data. The processed sequencing reads were aligned by HiSat2 (version 2.1.0) [28] to the human (UCSC hg38) or mouse genome (UCSC mm39). SmallRNA-seq reads were aligned by Bowtie2 (version 2.3.5.1) [29] to the mouse genome (UCSC mm10). RNA-seq reads of transgenic mouse tumor samples was corrected for a determined batch effect using ComBat-seq from R package sva (version 3.46.0) [30]. Differential gene expression was determined using the R package edgeR (version human: 3.32.0, mouse: 3.40.0) [31] utilizing trimmed mean of M-values (TMM) [32] normalization. A false discovery rate (FDR) value below 0.05 was considered as threshold for the determination of differential gene expression. Principal component analysis (PCA) on normalized fragments per kilobase of transcript per million fragments mapped (FPKM) and filtered genes with zero expression was performed by the prcomp function within the R environment. R package factoextra (https://rpkgs.datanovia.com/factoextra/; version 1.0.7) was used for visualization of PCA results. Copy number (CN) variations from sWGS data was determined

using the R package cn.Mops (version human: 1.36.0, mouse: 1.44.0) [33]. For determination of the ADRN/MES signature for mouse tissues, previously published gene sets were used [33]. Human ADRN/MES gene symbols were homology converted to mouse gene symbols by using the R package biomaRt (version 2.54; Supplementary Table 1) [34]. Public neuroblastoma sequencing data were analysed through the web application provided in the respective publication (https://www.neuroblastomacellatlas.org/) [35].

Quantitative analyses of copy number data. For copy number analysis, threshold values were set to known log2 ratios of -0.4 and +0.3 associated with losses and gains, respectively [36]. Identification of balanced and unbalanced 17q samples is based on median CN fold change comparing the whole 17p region (17p) with the 17q region from IGF2BP1 locus to 17q-ter (IMP1-ter). A balance value (bv) is determined on linear regression model, separating each sample into balanced or unbalanced 17q. Linear regression is defined as $bv = (-IMP1\text{-}ter + 17p + 0.2)$, resulting in unbalanced if $bv \leq 0$ and balanced if $bv > 0$. Identification of *MYCN*-amplified samples is based on CN of the *MYCN* locus (CN > 4 as MNA). Visualization of CN changes and comparison of gain and loss regions was performed with the R package karyoploteR (version 1.24.0) [37]. Genome conversion of coordinates and annotations between mouse and human assemblies was performed using USCS Lift Genome Annotations (https://genome.ucsc.edu/cgi-bin/hgLiftOver).

Pan-cancer loss-of-function analysis. To identify essential genes in MNA neuroblastoma, pan-cancer loss-of-function CRISPR screens of 620 cancer cell lines from different primary diseases were utilized for dependency analysis, using the Broad Institute Cancer Dependency Map (DepMap) portal (version 19Q3) [38]. 13 MNA cell lines (MYCN CN > 4) were selected from 46 available neuroblastoma cell lines and compared against 607 non-neuroblastoma cell lines (referred to as others). Subsequently, all available genes were filter by minimum expression (log2 TPM > 2) in at least 11 of 13 MNA cell lines (~ 85%). Median dependency was calculated for remaining genes across MNA and others, filtering for essential genes in both groups by a median below -0.2 and above -0.3 for MNA and others, respectively. Following, genes not present in both groups or to be considered as common

essential genes, retrieved by DepMap, were removed. For the final identification of MNA essential genes in neuroblastoma, significance in dependency changes between MNA and other cell lines were determined, performing a two-group comparison across the remaining genes by parametric empirical Bayes method provided by the Limma R package [39]. A FDR value below 0.05 was considered as threshold for significant essential genes in MNA (Supplementary Table 2).

Survival analysis. Survival analysis were performed using TMM normalized expression data. MRNAs were expression filtered (at least 1 FPKM in sum across all samples) and separated by the respective median of log2-transformed expression values. Log-rank test was performed with R package survival (version 3.2-11, https://CRAN.R-project.org/package=survival). Survival analysis for IGF2BP1 and MYCN expression was determined by best cut-off method. Multi-variate cox regression was performed using the coxph funtion of the R package survival (version 3.4.0) via an in-house R script. Survival analysis upon *MYCN* amplification and/or 17q unbalancing was performed based on determined CN. Of 100 tumors one was lacking survival data and for three samples RNA sequencing failed, resulting in different amount of total samples depending on analysis (Fig. 1; Supplementary Fig. 1, 8).

Gene set enrichment analysis. Gene set enrichment analysis (GSEA) [40] was performed using the R package clusterProfiler (version 4.6.0) [41] and MSigDB (version 2022.1) [42] gene sets with a minimum set size of 10 and no upper size restriction (Supplementary Table 3). Mouse gene symbols were homology converted to human symbols by using the R package biomaRt (version 2.54) [34].

IGF2BP1 CLIP studies. IGF2BP1 eCLIP (enhanced crosslinking and immunoprecipitation; Supplementary Table 4) peak data of Hep-G2 and K-562 cells were obtained from the ENCODE portal (www.encodeproject.org; ENCODE Project Consortium, 2012; identifiers ENCFF486BXN, ENCFF976DBP and ENCFF435MEM, ENCFF701YCW, respectively). IGF2BP1 eCLIP data of hESCs were obtained from the Gene Expression Omnibus (GEO; sample IDs GSM2071742 and GSM2071745).

RNA modification analysis. N^6-Methyladenosine (m^6A) modification sites were identified using the RNA Modification Database, RMBase (version 2.0) [43].

MYCN ChIP-seq analysis. MYCN ChIP-seq (chromatin immunoprecipitation sequencing; Supplementary Table 5) data was obtained from ChIP-Atlas [44] database for 9 untreated neuroblastoma-derived cell lines (BE(2)-C, CHP-134, COG-N-415, KELLY, LA-N-5, NB-1643, NB69, NGP, SK-N-BE(2)), comprising 15 experiments (SRX1690205, SRX5662024, SRX5662025, SRX5662026, SRX6935370, SRX1690210, SRX2550934, SRX3542258, SRX6935374, SRX2550935, SRX6935376, SRX6935379, SRX1690213, SRX2550933, SRX1178181).

E-Box motif locations. Locations of E-Box sequences were determined via an in-house R script using pattern matching of the MYC/N E-Box motif (CANNTG) at investigated sequences [45].

IGF2BP1 and transcription factor correlation analysis. For distinct transcription factors and IGF2BP1 the Spearman correlation coefficients with all annotated genes were determined in two independent human neuroblastoma datasets (the here presented and Kocak dataset from R2). Correlation coefficients for IGF2BP1 were then plotted against the correlation coefficients for a specific transcription factor to analyze the correlation between the IGF2BP1- and transcription factor-associated gene expression signature.

Cell culture and siRNA transfection. BE(2)-C (ATCC, CRL-2268) cells were cultured in a 1:1 mixture of DMEM/F12 (with HEPES, Gibco) and EMEM (ATCC); KELLY (DSMZ, ACC 355), SHEP-TET21N (legal MTA agreement from Prof. Schwab at the DKFZ, CVCL_9812) and HEK293T17 (ATCC, CRL-11268) cells were cultured in DMEM (Gibco) and NBL-S (DSMZ, ACC-656) cells were cultured in IMDM (Gibco) all supplemented with 10% FBS. Cells were grown at 37°C and 5% CO_2. Neuroblastoma cell lines (BE(2)-C, KELLY, SHEP-TET21N, NBL-S) were authenticated at Eurofins Genomics by 16 independent PCR systems (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317, D16S539, D2S1338, AMEL, D5S818, FGA, D19S433, vWA, TPOX and D18S51) and compared to online databases of the DSMZ and Cellosaurus. For siRNA knockdown 4 x 10^5 BE(2)-C, 1.5 x 10^6 KELLY or 5 x 10^5 TET21N cells were

transfected on a 6-well plate using 7.5 μl Lipofectamine RNAiMAX (Thermo Fisher Scientific) and 50 pmol siRNA according to the manufacturer's instructions. For the production of lentiviral particles, 3.6×10^6 HEK293T17 cells were transfected on a 6-well plate with 7 μl Lipofectamine 3000 (Thermo Fisher Scientific), the packaging plasmids psPax2 (3 μg) and pMD2.G (1.5 μg) as well as the lentiviral expression vector pLVX (4 μg) encoding iRFP. 2 μl P3000 per μg DNA were added. For luciferase reporter studies 5×10^4 BE(2)-C or 1.25×10^5 KELLY or NBL-S cells were transfected on a 24-well plate with 1 μl Lipofectamine 2000 (Thermo Fisher Scientific) and 200 ng pmirGLO vector. For genomic deletion of IGF2BP1 via CRISPR/Cas9 5×10^5 cells were transfected on a 6-well plate using 3.75 μl Lipofectamine 3000, 2 μg Cas9- and 1 μg sgRNA-encoding plasmids. For mRNA or protein decay analyses cells were treated with actinomycin D (5 μM, Sigma Aldrich) or emetin (100 μM, Sigma Aldrich) respectively for indicated time points. Plasmids and siRNAs used are summarized in Supplementary Table 6.

CRISPR/Cas9 knockout generation. For the CRISPR/Cas9-mediated genomic deletion of IGF2BP1, cells were transfected with two CRISPR sgRNA-encoding (psg-RFP-IGF2BP1 Exon6 and psg-RFP-IGF2BP1 Exon7) and a Cas9 nuclease-encoding (pcDNA-Cas9-T2A-GFP) plasmid. 48h post transfection cells were sorted for single cell clones by seeding one RFP- and GFP-positive cell per 96-well using a FACS Melody sorter (BD Bioscience). The deletion of IGF2BP1 was validated by western blotting. CRISPR sgRNAs and plasmids are summarized in Supplementary Table 6.

Lentiviral transduction. HEK293T17 cells were transfected as described in *Cell culture and siRNA transfection*. Lentiviral particle-containing supernatant was collected 24 and 48 h post transfection and stored at -80 °C. Titers were analyzed 72 h post infection of 5×10^4 HEK293T17 cells and determined by flow cytometry (iRFP) using a MACS Quant Analyzer (Miltenyi BioTech). Lentiviral transduction for downstream experiments was accomplished at 5 MOI (multiplicity of infection).

Luciferase assay. The MYCN and BIRC5 3´UTR was amplified from genomic DNA and cloned in the pmirGLO plasmid. Mutated MYCN 3´UTR was designed by mutation of following miRNA seed regions: miR-34a, miR-19, miR-29, miR-101, let-7 and miR-17-92 and ordered from GenScript Biotech. 36 h

post transfection, Dual-Glo luciferase reporter analyses were performed according to manufacturer´s protocol. Ratios of Firefly to Renilla activity were calculated and the activity of the 3´UTR reporters were normalized to the respective controls. For luciferase assays with BTYNB, medium was changed 6 h post transfection and DMSO or BTYNB was added at EC_{50} concentration. Reporter containing a minimal vector-encoded 3´UTR served as normalization control. Primers and plasmids are summarized in Supplementary Table 6.

Spheroid formation and anoikis assay. For spheroid growth assay 2×10^3 cells were seeded in a 96-well round-bottom ultra-low attachment plate (Corning) with 10% FBS. Spheroid formation was induced by centrifugation for 5 minutes at 2000 rpm. Five days post seeding images were acquired using an IncuCyte S3 (Sartorius). For anoikis assay 1×10^3 cells were seeded in a 96-well flat-bottom ultra-low attachment plate (Corning) with 1% FBS. Five days post seeding cells were transferred to a round-bottom plate, centrifuged for 5 minutes at 2000 rpm and then images were acquired using an IncuCyte S3 (Sartorius). Cell viability and caspase 3/7 activity was measured with CellTiter Glo (Promega) or Caspase Glo (Promega) respectively according to manufacturer´s protocol.

RNA immunoprecipitation. For RNA immunoprecipitations (RIP) cell extracts (3.5×10^6 BE(2)-C or 12.5×10^6 KELLY and NBL-S) were prepared on ice using RIP buffer (10 mM HEPES, 150 mM KCl, 5 mM $MgCl_2$, 0.5% NP40, pH 7.0). Cleared lysates were incubated with anti-IGF2BP1 or anti-AGO2 antibody and Protein G Dynabeads (Life Technologies) for 30 min at room temperature. After three washing steps with RIP buffer, protein-RNA complexes were eluted by addition of 1% SDS and 65°C for 5 minutes. Protein enrichment was analyzed by western blotting. Co-purified RNAs were extracted using TRIzol and analyzed by RT-qPCR. If indicated, DMSO or 5 µM BTYNB was added 6 h before RIP was performed.

Western blotting. Infrared western blotting analyses were performed as previously described [20]. Vinculin (VCL/Vcl) served as a loading and normalization control. For RIP analyses VCL served as negative control. For the miTRAP study VCL served as negative control and MS2-BP as control for equal loading of the resin. Antibodies used are indicated in Supplementary Table 6.

RNA isolation and RT-qPCR. Total RNA from cell lines were isolated using TRIzol. RNA concentration was determined by nanodrop (Tecan Spark). For cDNA synthesis, 2 µg total RNA served as a template using M-MLV Reverse Transcriptase (Promega) and random hexamer primers following manufacturer´s protocol. For RNA decay analyses Oligo-dT primers were used instead of random hexamer primers. RT-qPCR analyses were performed on a LightCycler 480 II (Roche) with the ORA^{TM} qPCR Green ROX L Mix (highQu). In general, RPLP0, EEF2 and GAPDH served as housekeeping genes (normalization controls). For RNA decay analyses RPLP0 served as normalization control. For IGF2BP1 RIP assays RNA data are input normalized and HIST1 served as normalization control. E2F1 served as a positive control. For AGO2 RIP assays RNA data are input normalized and IGF2BP1-KO cells were normalized against control cells. Primer pairs were selected using Primer Blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Sequences are summarized in Supplementary Table 6. Relative RNA abundance was determined by the $\Delta\Delta C_t$ method, as previously described [20].

Nascent RNA capture. For analyzing the newly synthesized RNA the Click-iT^{TM} nascent RNA capture kit (Invitrogen) was used according to manufacturer´s instructions and as previously described [24].

miTRAP experiment. MiTRAP experiments using 3´UTR of MYCN or MS2 control RNA were essentially performed as described recently [46].

Drug analysis. For determining the EC$_{50}$ values 5×10^3 BE(2)-C, 1×10^4 NBL-S or 1.25×10^4 KELLY cells were seeded per well of a 96-well plate. A serial dilution of the drugs was performed and added to the cells at the indicated concentrations. DMSO served as control condition. After 72 h of treatment, an image was acquired using IncuCyte S3 (Sartorius). Confluence was determined using the IncuCyte software. Confluence values were normalized to DMSO control. For the analysis of synergy between two drugs, the cell viability was determined 72 h upon drug exposure using CellTiter GLO (Promega) in a drug matrix screen at indicated concentrations. Synergy relief maps were generated using the SynergyFinder web application (https://synergyfinder.fimm.fi; version 2.0) and the ZIP (Zero interaction potency) method [47]. For BTYNB recovery experiment DMSO or 5 µM BTYNB were added to the cells and grown for 72 h. Afterwards one third of the BTYNB-treated cells were

harvested (referred to as '3 days BTYNB') while the rest was treated further with DMSO ('BTYNB+DMSO 6 days' = recovery) or 5 µM BTYNB ('6 days BTYNB') respectively.

Animal handling and ethics approval. Animals were handled according to the guidelines of the Martin Luther University. Permission was granted by the state administration office of Saxony-Anhalt (reference number: 42502-2-1381 MLU, 42502-2-1530 MLU, 42502-2-1625 MLU). Female immunodeficient athymic nude mice (FOXN1$^{nu/nu}$) were obtained from Charles River. For subcutaneous xenograft assays 1 x 10^6 iRFP-labeled BE(2)-C or 2 x 10^6 iRFP-labeled NBL-S cells (stably transduced using iRFP encoding lentiviruses) were harvested in PBS supplemented with 50% (v/v) matrigel (Sigma) and injected into the left flank of six-week old mice. Prior injection, cells were counted using a TC20 Cell Counter (Bio-Rad). Subcutaneous tumor growth and volume were measured and monitored by non-invasive near-infrared imaging using a Pearl Impulse Imaging System (LI-COR) and isoflurane as anesthetic. Tumor volume was calculated using the formula $\pi/6 \times$ L1 × L2 × L3. For testing BTYNB *in vivo* BE(2)-C cells were treated for 24 h with BTYNB or DMSO prior to harvesting. For intra-tumoral application of BTYNB 5 x 10^5 iRFP-labeled BE(2)-C cells were injected into nude mice and grown for 2 weeks. Afterwards treatment was started by injecting 50 mg/kg body weight BTYNB in 100 µl 35% cyclodextrin solution in PBS with a DMSO concentration of 7%. Treatment was performed five days in a row followed by two days without compound application before the cycle started again. Transgenic mice were generated by Taconic Bioscience except of LSL-*MYCN* mice which were obtained from Prof. Schulte, Berlin. For getting a homogenous background, mice were backcrossed to C57Bl6/N mice (Charles River) and afterwards crossbred. Mouse genotyping was confirmed by PCR. Mice were palpated weekly for abdominal tumors. Mice are summarized in Supplementary Table 7. Primer sequences are provided in Supplementary Table 6. Patient-derived xenografts (PDX) were performed by EPO company in Berlin, Germany. The neuroblastoma tumor 14647 harboring *MYCN* amplification and 17q gain was implemented in NOG mice to generate PDX. Treatment was performed by intra-peritoneal application of DMSO, 100 mg/kg body weight BTYNB, 2.5 mg/kg body weight YM-155 or the combination of BTYNB and YM-155

in 100 µl 30% cyclodextrin solution in PBS with a final DMSO concentration of 7%. Compound application was done five days in a row followed by two days without treatment. Tumor volume and mouse weight was documented over time.

BTYNB synthesis and stability. BTYNB was synthesized starting from 5-Bromo-2-thiophenecarboxaldehyde and anthranilamide. In detail, a mixture of 5-Bromothiophene-2-carboxaldehyde (1 mmol) and anthranilamide (1 mmol) in ethanol (5 ml) was refluxed for 3 hours then cooled to room temperature. The precipitated solid was then filtered, washed with ethanol and hexane and air dried. Yield: 70%; Analytical characterization: MS m/z: 310.10 [M+H]+; 1H NMR (400 MHz, DMSO) δ 8.49 (s, 1H), 7.60 (dd, J = 7.7, 1.3 Hz, 1H), 7.31 – 7.22 (m, 2H), 7.06 (d, J = 3.8 Hz, 1H), 6.93 (d, J = 3.8 Hz, 1H), 6.78 – 6.64 (m, 2H), 5.95 (t, J = 2.2 Hz, 1H); HPLC: rt 11.31 min (Purity of BTYNB 97.77 %)

Chemical stability of BTYNB. A 10 µM BTYNB solution in acetonitrile was incubated with Dulbecco's Modified Eagle Medium (DMEM) at 37 °C, and samples were analyzed at different time intervals (0 min, 30 min, 60 min, 120 min, 24 h, 48 h and 72 h) using the HPLC method described below to determine and quantify potential degradation products. A good stability profile up to 72 h was obtained (Table 1; Supplementary Fig. 6e). In addition this protocol was used to test the stability of BTYNB under acidic conditions where the solution was incubated with 10% v/v of triflouroacetic acid in DMSO at 37 °C. A slight degradation of 15 % after 72 h was observed (Table 1; Supplementary Fig. 6f).

Table 1: BTYNB stability

condition	0h	6h	12h	24h	48h	72h
BTYNB in DMEM	100%	100.4 %	101.2 %	103.1 %	105.3 %	107.7 %
BTYNB in DMEM under acidic condition	100%	98.3 %	97.4 %	95.1 %	85.8 %	84.3 %

HPLC method. As HPLC system a LiChrosorb® RP-18 (5 µm) 100-4.6 column from the manufacturer Merck, two LC-10AD pumps, a SPD-M10A VP PDA detector, and a SIL-HT autosampler were used (all from the manufacturer Shimadzu, Kyoto, Japan). As mobile phase a gradient with increasing polarity

composed of methanol/water/triflouroacetic acid at a flow rate of 1 ml/minute was used. UV absorbance was measured at 254 nm.

Plasma protein binding of BTYNB. Serial dilutions of BTYNB in acetonitrile (0-100 μM) were prepared and their absorbance was measured by the described HPLC method to get a calibration curve. Next, a 100 μM solution of BTYNB in acetonitrile was incubated with fetal bovine serum (FBS) or human serum albumin (HSA; 40 mg/ml in PBS) and samples at different time intervals (0 min, 30 min, 60 min, 120 min, 24 h, 48 h and 72 h) were analyzed. The samples were subjected to ultra-centrifugation (5 min, 10000 rpm/g) using modified PES 30K low protein binding centrifugal filter. The filtrate was then analyzed using HPLC to determine the available concentration of BTYNB (using the previous calibration curve) and also to determine and quantify other potential degradation products. The obtained results showed that BTYNB has a very high plasma protein binding upon testing either in FBS or HAS (Supplementary Fig. 6g, h).

Human neuroblastoma samples. Human neuroblastoma cohort consists of 69 previously published untreated primary samples [48] extended by 31 additional tumor specimens. Tumors were granted after patient consent and ethical approval from the Cologne tumor bank and the Universitätsklinikum Essen, Germany (Supplementary Table 8). The International Neuroblastoma Staging System criteria (INSS) was used for staging.

Tissue preparation. Transgenic tumors and murine organs were dissected and shock-frozen on dry ice. Approximately 30 mg of frozen tissue was lysed, homogenized with Zirconium Oxide beads and Precellys 24 homogenizer (berting technologies) and lysates were subjected to the Qiagen AllPrep DNA/RNA/Protein Kit protocol, with the exception, that precipitated protein was solubilized in 5% SDS solution. Human tumor samples were handled as previously described [48].

Immunohistochemistry. Transgenic tumor samples were fixated with Roti®-Histofix (Roth) and embedded in paraffin. Paraffin blocks were sliced at 4 μm thickness using LEICA RM2235 (Leica) and transferred to a specimen slide. Staning was performed for hematoxylin and eosin as well as Phox2b.

Images were acquired using a Nikon Eclipse TE2000-E microscope with a 20x objective and 1.5 manual magnification.

Plasmids and cloning. Cloning strategies including vectors, oligonucleotides used for PCR and restrictions sites are summarized in Supplementary Table 6. All constructs were validated by sequencing.

Statistics and presentation. All experiments were at least performed in biological triplicates. Western blotting and genotyping PCR for transgenic mouse experiments were just performed once as in this case biological replicates are individual mice. The western blot for the miTRAP experiment was also done once as we performed four experiments in total and three off them went completely for miRNA sequencing. Statistical significance was tested by parametric two-sided Student´s t-test on equally distributed data (errors defined as standard deviation of the mean). This includes all lab-based analyses (western blot, RT-qPCR, drug assays, luciferase assays, viability measurements). Otherwise, a non-parametric two-sided Mann-Whitney-test was performed (error defined as standard error of the mean). This includes all tumor-related analyses (human neuroblastoma samples, transgenic mouse and xenograft data). For box plots, horizontal lines demonstrate the median with upper and lower box boundaries demonstrating the 25th-75th centiles. Error bars represent the maximum and minimum (Fig. 3g, h; Supplementary Fig. 6d). For Kaplan-Meier survival analyses, statistical significance was determined by log-ranked test. No testing for outliers were performed. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$. Data were visualized with GraphPad Prism (version 8.0.1). Heatmaps were generated with Flourish web application (https://flourish.studio/). Biorender (https://www.biorender.com/) was used for generation of some figures.

Results

MNA neuroblastoma essential genes are enriched on chromosome 17q

Gene expression and genomic aberrations in neuroblastoma were analyzed in 100 tumors, representing all INSS stages (Supplementary Table 8). Shallow whole genome sequencing (sWGS) identified common chromosomal gains and deletions (Fig. 1a; Table 2) [1, 2]. The most frequent disturbances were gains at Chr 17 with 35 tumors showing uneven copy number of 17q and 17p (referred to as unbalanced 17q).

Table 2: Chromosomal aberrations in neuroblastoma

chromosomal region	genomic aberration	frequency	frequency literature	references
1p	loss	10%	30-40%	[2, 49]
2p	gain	23%	20-35%	[2, 49]
3p	loss	24%	18%	[50]
4p	loss	14%	20%	[2]
7	gain	44%	40%	[51]
11q	loss	27%	29-44%	[2, 49, 50]
14q	loss	20%	22-25%	[2, 49]
17q	gain	79%	> 50%	[2, 49]
unbalanced 17q	gain	35%	-	

Survival analyses demonstrated association of unbalanced 17q with poor survival (Fig. 1b). Adverse prognosis was fostered by concomitant *MYCN* amplification (Fig. 1b). Reduced survival probability was confirmed for the 17 MNA tumors compared to *MYCN* non-amplified (nMNA) tumors (Fig. 1c). Only few tumors (n = 4) with balanced 17q and MNA were observed prohibiting conclusive survival analyses (Supplementary Fig. 1a). This suggested pro-oncogenic association of 2p gain and unbalanced 17q in neuroblastoma.

To identify essential candidate genes, we analyzed gene dependency scores via the DepMap portal [38] for 13 MNA neuroblastoma and 607 non-neuroblastoma cell lines. This revealed 177 genes (175 autosomal, 2 gonosomal) with increased essentiality in MNA neuroblastoma. *MYCN*, *ISL1* and *HAND2* were the top-ranked genes (Supplementary Table 2). Only for Chr 17, significant enrichment of essential genes, with top ranking of *IGF2BP1*, *GJC1* and *MSI2,* was observed (Fig. 1d, e; Table 3).

Table 3: Hypergeometric testing for distribution of neuroblastoma essential genes

Chr	protein coding genes	NB essential genes	% distribution	p-value
1	2048	22	12.6%	0.2496822
2	1247	17	9.7%	0.0668034
3	1075	4	2.3%	0.9904822
4	751	5	2.9%	0.8245106
5	886	4	2.3%	0.9651801
6	1047	6	3.4%	0.9238733
7	917	4	2.3%	0.9716455
8	683	3	1.7%	0.9527968
9	781	5	2.9%	0.8492704
10	731	4	2.3%	0.9076264
11	1311	6	3.4%	0.9835301
12	1035	10	5.7%	0.4815816
13	321	3	1.7%	0.5682151
14	612	0	0.0%	1
15	599	7	4.0%	0.3128974
16	853	5	2.9%	0.8971414
17	**1188**	**52**	**29.7%**	**5.047e-22**
18	268	3	1.7%	0.4479059
19	1471	9	5.1%	0.9305177
20	546	2	1.1%	0.9626367
21	232	0	0.0%	1
22	444	4	2.3%	0.5853077

Chr – chromosome; NB – neuroblastoma

This further supports the previously proposed prognostic value of IGF2BP1 [14] in neuroblastoma, as observed here in low- and high-risk subgroups except MNA (Fig. 1f; Supplementary Fig. 1b-f). In agreement, unbalanced 17q is associated with adverse outcome in nMNA tumors (Supplementary Fig. 1g, h). Cox multi-variate analyses validated MNA, unbalanced 17q as well as IGF2BP1 and MYCN expression as independent predictors of poor outcome (Table 4).

Table 4: Cox multi-variate analyses

condition	HR	p-value	assumption test
MNA	20.4	5.05e-10	0.19794462
unbalanced Chr 17	8.2	1.56e-4	0.09810777
IGF2BP1	1.4	0.0213	0.22645191
MYCN	1.54	1.30e-6	0.08137129

HR – hazard ratio; MNA – *MYCN* amplification; Chr – chromosome

However, IGF2BP1 showed strong association with MYCN and was significantly increased in MNA, unbalanced 17q, INSS-4 and deceased patients (Supplementary Fig. 1i-m). Correlation analyses in two independent tumor cohorts showed substantial relation of IGF2BP1- and MYCN-associated gene

expression (Supplementary Fig. 1n). This was less pronounced for other transcriptional regulators like the neuroblastoma core regulatory circuit [52] member PHOX2B (Table 5).

Table 5: Correlation of IGF2BP1- and MYCN-associated gene expression

gene	Bell		Kocak	
	R Spearman	p value	R Spearman	p value
MYCN	0,9286	< 0,0001	0,7306	< 0,0001
PHOX2B	0,7359	< 0,0001	0,4511	< 0,0001
GATA3	0,7351	< 0,0001	0,5584	< 0,0001
HAND2	0,7193	< 0,0001	0,2191	< 0,0001
SOX4	0,6696	< 0,0001	0,0270	0,0005
NFκB	0,5332	< 0,0001	- 0,4308	< 0,0001
PRRX1	- 0,1866	< 0,0001	- 0,1979	< 0,0001

Depletion studies in MNA and 17q unbalanced BE(2)-C cells confirmed association of deregulated gene expression upon MYCN and IGF2BP1 knockdown (Supplementary Fig. 1o). Public neuroblastoma single cell RNA-seq data [35] indicated nearly exclusive expression and strong association of IGF2BP1 and MYCN expression in tumor cell populations (Supplementary Fig. 1p, q). Collectively, this suggested an interconnected disease driving role of IGF2BP1 and MYCN in HRN.

IGF2BP1 is a post-transcriptional enhancer of MYCN expression

We demonstrated that IGF2BP1 modulates MYCN expression in neuroblastoma cell models [14, 53], but the underlying mechanisms and potential synergy of both in promoting HRN remained elusive. IGF2BP1-CLIP studies in hESCs indicated association of IGF2BP1 at the MYCN 3´UTR (Supplementary Fig. 2a). The deletion (KO) of IGF2BP1 consistently reduced MYCN protein and mRNA expression in three neuroblastoma cell lines (Fig. 2a; Supplementary Fig. 2b). In line with IGF2BP1's main role in cancer [20, 21, 54], IGF2BP1-KO significantly decreased MYCN mRNA half-life in BE(2)-C (Fig. 2b). IGF2BP1-RIP confirmed pronounced association of IGF2BP1 with the validated target mRNA E2F1 [24] as well as MYCN transcripts (Fig. 2c; Supplementary Fig. 2c, 3a). Recent miTRAP (microRNA trapping by RNA affinity purification [46]) studies indicated miRNA and AGO2 association with the MYCN 3'UTR in BE(2)-C [53]. Likewise, miTRAP demonstrated association of IGF2BP1 with the MYCN 3´UTR (Fig. 2d). This suggested that MYCN expression is druggable by BTYNB, a small molecule inhibitor of

IGF2BP1-mRNA association impairing IGF2BP1-driven E2F1 and MYC expression [24]. BTYNB decreased neuroblastoma cell viability, as previously reported [55], disturbed MYCN mRNA association with IGF2BP1 and impaired MYCN at only modest reduction of IGF2BP1 (Fig. 2e-g; Supplementary Fig. 2d, e, 3b). MYCN decrease was pronounced by extended treatment and recovered after compound withdrawal, indicating that BTYNB reversibly impairs IGF2BP1-stimulated expression of MYCN.

Whether IGF2BP1-dependent regulation of MYCN is miRNA-dependent was investigated by AGO2-RIP. IGF2BP1-KO significantly increased association of AGO2 with the MYCN mRNA (Fig. 2h; Supplementary Fig. 3c). This was analyzed further by luciferase reporters lacking a native 3'UTR (control) and comprising the wildtype (wt) or mutated (mut) MYCN 3'UTR. In the latter, >90% of predicted/validated miRNA targeting sites were inactivated by mutation (Fig. 2i, j; Table 6).

Table 6: Validated and predicted miRNA-binding sites for MYCN

miRNA family	miRNA binding	binding site (MYCN 3´UTR bp)	luciferase reporter
miR-34-5p	validated	22-29	mutated
miR-19-3p	validated	31-38	mutated
miR-29-3p	validated	332-339	mutated
miR-101-3p	validated	493-500	mutated
let-7-5p/miR-98-5p	validated	505-511	mutated
miR-101-3p	validated	562-568	wildtype
miR-34-5p	validated	579-585	mutated
miR-302-3p	predicted	858-864	mutated
miR-17-5p/20-5p/93-5p/106-5p	predicted	859-865	mutated
let-7-5p/miR-98-5p	validated	868-874	mutated

miRNA – microRNA; 3´UTR – 3´ untranslated region; bp – base pairs

Activity of the wt reporter was consistently reduced in comparison to control and mut reporters, confirming conserved miRNA-dependent regulation of the MYCN 3'UTR in neuroblastoma cell models (Fig. 2k; Supplementary Fig. 2f, g). Both, IGF2BP1-KO and BTYNB, further decreased wt reporter activity, whereas the mut reporter remained unaffected (Fig. 2l; Supplementary Fig. 2h). This indicated that BTYNB disrupts miRNA-dependent regulation of MYCN by IGF2BP1.

IGF2BP1-dependent stabilization of some target mRNAs, e.g. MYC and E2F1, is enhanced by m^6A modification via the METTL3/14 methyltransferase complex [24]. To test if this is also observed for

the m^6A-modified MYCN mRNA (Supplementary Fig. 4a), was analyzed by METTL3/14 co-depletion. Knockdown reduced E2F1 protein and mRNA abundance without affecting IGF2BP1 expression (Supplementary Fig. 4b-d), as prior reported [24]. However, MYCN protein and mRNA levels remained unchanged, suggesting that IGF2BP1 promotes MYCN expression largely independent of m^6A, but in a 3'UTR-, miRNA- and BTYNB-dependent manner.

IGF2BP1 is an essential and druggable driver of neuroblastoma growth

Our findings suggested, IGF2BP1 as a novel driver of neuroblastoma. IGF2BP1-KO consistently decreased spheroid growth and anoikis resistance, whereas caspase 3/7 activity (apoptosis) was moderately increased (Fig. 3a, b; Supplementary Fig. 5a, b). In subcutaneous (s.c.) xenografts, IGF2BP1-KO impaired tumor engraftment, MYCN expression and delayed growth by 5-7 days (Fig. 3c-g; Supplementary Fig. 5c-f). This was also observed by BTYNB pre-treatment of parental cells (Fig. 3h). How the intra-peritoneal (i.p.) delivery of BTYNB affects growth of an MNA and 17q unbalanced s.c. patient-derived xenograft (PDX) was analyzed by three cycles of treatment at 100 mg/kg body weight (BW). Notably, treatment showed no obvious toxicity (Supplementary Fig. 6a). Tumor growth was only slightly reduced by BTYNB (Fig. 3i). This rather moderate potency is probably due to high plasma protein binding of BTYNB, suggesting poor pharmacokinetics (Supplementary Fig. 6e-h). Aiming to overcome these limitations, s.c. BE(2)-C xenograft tumors were treated with two cycles of intra-tumoral (i.t.) BTYNB application at 50 mg/kg BW (Fig. 3j; Supplementary Fig. 6b-d). As for i.p. treatment, no obvious signs of toxicity were observed. However, i.t. treatment substantially impaired tumor growth, indicating strong target potential of IGF2BP1 and therapeutic lead prospects of BTYNB.

MYCN and IGF2BP1 form a druggable positive feedforward loop in neuroblastoma

MYC promotes IGF2BP1 transcription [56]. In view of MYC/N similarity [57] and strongly associated expression of IGF2BP1 and MYCN in neuroblastoma (Supplementary Fig. 1i), we hypothesized that MYCN promotes IGF2BP1 transcription as well. Public MYCN ChIP-seq data [44] indicated conserved association of MYCN at the *IGF2BP1* promoter and coverage of several E-Box motifs (Fig. 4a). MYCN depletion substantially reduced steady state level and nascent transcript synthesis of IGF2BP1, indicating MYCN-driven IGF2BP1 transcription and feedforward regulation of MYCN/IGF2BP1 (Fig. 4b, c; Supplementary Fig. 7a). To test if this is also druggable via MYCN, we explored four bromodomain inhibitors (BRDi: Mivebresib, ARV-771, CPI-0610, INCB-057643), which impair MYC/N abundance and transcriptional activity (Fig. 4d) [58, 59]. In MNA cells, BRDi concisely decreased IGF2BP1 and MYCN expression with the most robust downregulation observed by Mivebresib (Fig. 4e; Supplementary Fig. 7b, c). In contrast, MYCN and IGF2BP1 expression remained unaffected by BRDi in nMNA NBL-S, in which MYCN synthesis is elevated by genomic translocation (Supplementary Fig. 7c) [60]. In view of MYCN/IGF2BP1 feedforward regulation, it was expected that IGF2BP1 alters sensitivity to BRDi and BTYNB (IGF2BP1i) synergizes with BRDi in non-MYCN-translocated neuroblastoma. IGF2BP1-KO severely reduced EC_{50} values for Mivebresib (~7-fold) and drug matrix screens confirmed substantial benefit of combined treatment (maximum synergy score = 19-21) exclusively in MNA cells (Fig. 4f, g; Supplementary Fig. 7d-f). This suggested effective targeting of MYCN/IGF2BP1 by combined BRDi and IGF2BP1i in MNA neuroblastoma.

IGF2BP1/MYC(N)-driven genes on Chr 17q harbor therapeutic potential in cancer treatment

Feedforward regulation by MYCN/IGF2BP1 likely impact many effectors due to broad target spectra [57, 61], suggesting MYCN/IGF2BP1 also synergize with oncogenic genes located on Chr 17q. This was evaluated for selected oncogenes/tumor suppressors (control) and essential genes located at Chr 17q by integrating: i) gene dependency score in MNA neuroblastoma cell lines, ii) fold change of mRNA in 17q unbalanced, MNA or INSS-4 tumors, iii) gene hazardous ratio, iv) correlation of mRNA expression with MYCN and IGF2BP1 in tumors, v) fold change of mRNA upon MYCN and IGF2BP1

depletion, vi) MYCN ChIP-seq data, vii) IGF2BP1-CLIP data (Supplementary Fig. 8a; Supplementary Tables 2, 4, 5, 9). Next to *IGF2BP1*, this analysis unraveled top-ranking of *BIRC5* and *TOP2A* among common essential as well as *NME1* among neuroblastoma essential Chr 17q genes. This was further evaluated for the oncogene BIRC5, which was proposed for targeted treatment (BIRC5i) of various cancers including HRN (Supplementary Fig. 8b-g) [26, 62-64]. Regulation by MYCN/IGF2BP1 was confirmed by: i) BIRC5 downregulation upon MYCN and IGF2BP1 depletion, ii) ChIP-seq data indicating conserved MYCN association at the *BIRC5* promoter, iii) IGF2BP1-CLIP demonstrating conserved IGF2BP1 association at the BIRC5 3'UTR, iv) reduced activity of BIRC5 3'UTR luciferase reporters upon IGF2BP1-KO and IGF2BP1i by BTYNB (Fig. 5a-c; Supplementary Fig. 8h, i). Like observed for BRDi, IGF2BP1-KO reduced EC_{50} values (~3-fold) for BIRC5i by YM-155 (Fig. 5d), which was well tolerated in clinical trials and showed anti-tumor activity in combination therapy [26, 63, 64]. Accordingly, we investigated the response of MNA/17q unbalanced s.c. PDX tumors to YM-155 (2.5 mg/kg BW) and combined i.p. treatment with BTYNB (100 mg/kg BW). Although results remained non-significant, YM-155 modestly reduced tumor growth and this was further enhanced in combination with BTYNB (Fig. 5e). Drug matrix analyses in MNA cells supported a moderate benefit of combined BTYNB/YM-155 treatment (Fig. 5f; Supplementary Fig. 8j). In sum, this suggested that IGF2BP1 is a potent, druggable oncogene in neuroblastoma synergizing with MYCN in a transcriptional/post-transcriptional feed-forward loop resulting in the upregulation of oncogenes like the 17q-located BIRC5 (Fig. 5g).

IGF2BP1 is a strong oncogenic driver of neuroblastoma and promotes MYCN protein stability

Aiming to test IGF2BP1's oncogenic potential in a sympatho-adrenal neuroblastoma model, we established transgenic LSL-*IGF2BP1*-IRES-iRFP mice (Supplementary Fig. 9a), essentially as previously described for MYCN and Lin28b [65, 66]. Notably, the ~9 kb IGF2BP1 3'UTR was discarded to enhance expression by preventing miRNA-directed downregulation, primarily by let-7 miRNAs [22]. Conditional transgene expression in adrenal glands and peripheral nerves was induced by *Dbh*-driven

iCRE. Heterozygous or homozygous transgene integration at the *Rosa26* (*R26*) locus was validated for

all analyzed animals by gDNA-PCR (Supplementary Fig. 9-12). LSL-*IGF2BP1* mice were fertile without

any obvious phenotypes and offspring were born according to Mendelian ratio. No tumors were

observed in controls, LSL-*IGF2BP1* or *Dbh*-iCRE (data not shown). Heterozygous R26$^{IGF2BP1/-}$ mice only

showed low tumor burden (1/8) within one year (Fig. 6a). In sharp contrast, homozygous

R26$^{IGF2BP1/IGF2BP1}$ mice developed tumors with an incidence of 100% (7/7; Fig. 6a). Ethical culling was

required after 169-305 d (median survival 234 d), suggesting a strongly IGF2BP1-dose dependent

tumor induction. Seven out of eight IGF2BP1-induced tumors resided in the lower abdomen,

potentially arising from sympathetic nerves, and only one homozygous tumor was derived from the

adrenal gland (Fig. 6b). In contrast to other neuroblastoma models, no other primary tumor sites, like

the superior cervical ganglia, were observed [65-67]. Surprisingly, no tumors (0/6) were found in the

Dbh-driven heterozygous R26$^{MYCN/-}$ model. Strikingly, however, tumor incidence increased to 100%

(8/8) and median survival was reduced to 107 d in R26$^{IGF2BP1/MYCN}$ mice, validating a strong synergy of

IGF2BP1 and MYCN in promoting neuroblastoma (Fig. 6a). Moreover, R26$^{IGF2BP1/MYCN}$ substantially

elevated tumor burden per animal with 19 tumors observed in 8 animals. Of these, 75% harbored

tumors derived from adrenal glands, 62.5% contained abdominal tumors and 50% showed tumors

along the spine (Fig. 6b). Inspection of tumors indicated neuroblastoma characteristic small round

blue tumor cell morphology and elevated nuclear Phox2b protein (Fig. 6c). Principal component

analyses of RNA-seq data derived from tumors and/or adrenal glands revealed no striking differences

in respect to tumor location or between R26^{IGF2BP1} and R26$^{IGF2BP1/MYCN}$ tumors (Fig. 6d; Supplementary

Fig. 9c). The investigation of adrenergic (ADRN) versus mesenchymal-like (MES) gene expression

signatures [33], suggested mesenchymal-like pattern in wildtype (AG) and R26$^{MYCN/-}$ (AGM) adrenal

glands (Fig. 6e). In sharp contrast, rather adrenergic neuroblastoma was observed in both, R26^{IGF2BP1}

(TI) and R26$^{IGF2BP1/MYCN}$ (TIM) tumors. In support of MYCN/IGF2BP1-driven expression of 17q

oncogenes, e.g. BIRC5, TI and TIM samples showed elevated expression of Mycn, Igf2bp1 and Birc5,

whereas Myc was diminished (Fig. 6f). This was associated with elevated expression of

neuroblastoma (e.g. Phox2b), sympatho-adrenal (e.g. Th), neural (e.g. Gap43), neural stem cell (e.g.

Msi1) and neural crest cell markers (e.g. Tfap2b) [65, 68]. At the protein level, transgene dose-dependent upregulation of IGF2BP1/Igf2bp1 was observed in non-tumorous adrenal glands and further fostered in tumors (Fig. 6g). The investigation of MYCN/Mycn protein abundance in adrenal glands and tumors revealed a striking IGF2BP1-dependent increase without obvious association of altered mRNA levels (Fig. 6h). This suggested IGF2BP1-dependent modulation of MYCN protein turnover (Fig. 6i), since the *MYCN* transgene lacks the native 3'UTR. In support of this, IGF2BP1 depletion decreased MYCN protein levels in TET21N, lacking the native MYCN 3'UTR (Fig. 6j) [69]. In emetine treated TET21N, MYCN protein showed an approximately 2-fold decreased half-life upon IGF2BP1 knockdown (Fig. 6k; Supplementary Fig. 13a), indicating that IGF2BP1 promotes both, MYCN mRNA and protein stability. Investigation of key regulators controlling MYCN protein turnover [70], revealed upregulation of stabilizing factors (Aurka, Plk1, Cdk1) especially in TI (Fig. 6l). Their abundance was decreased by IGF2BP1 depletion in human neuroblastoma cells without striking effects on post-translational modifications (Fig. 6m, n; Supplementary Fig. 13b). In contrast, no obvious association was observed for IGF2BP1 and factors destabilizing MYCN protein, primarily GSK3B/Gsk3b and FBXW7/Fbxw7. This indicated that IGF2BP1 promotes MYCN protein stability, probably by the previously described RNA-dependent enhancement of AURKA [54] and additional upregulation of PLK1 and CDK1.

IGF2BP1 induces high-risk neuroblastoma with 2p/17q syntenic chromosomal aberration

The genomic landscape of MYCN/IGF2BP1-induced neuroblastoma was analyzed by sWGS performed on AGM, TI, TIM and murine wildtype adrenal glands. Barely any expanded chromosomal aberrations were observed in AGM, supporting lack of tumor induction (Supplementary Fig. 14a). TIM samples only showed modest (<20 %) gains at Chr 11 and pronounced (up to 50%) gains at Chr 6, whereas barely any deletions were observed (Fig. 7a). In contrast, chromosomal deletions (mainly at Chr 4, 6, 9, 14, and 16) were expanded in TI samples (Fig. 7b). Most strikingly, however, substantial gains (>50-70 %) were found at Chr 11 (*Igf2bp1*) and Chr 12 (*Mycn*) in TI samples. Chromosomal lift-over

analyses (mouse to human) indicated that R26^{IGF2BP1} induces chromosomal gains reminiscent to 2p

(*MYCN*) and 17q (*IGF2BP1*) amplification observed in human HRN (Fig. 7c).

GSEA based on RNA-seq data revealed substantial upregulation of pro-proliferative

(E2F_TARGETS, G2M_CHECKPOINT) and downregulation of tumor-suppressive (P53_PATHWAY,

APOPTOSIS) hallmark gene sets in TI and TIM samples (Fig. 7d; Supplementary Table 3). Consistent

with strong elevation of MYCN/Mycn expression, canonical MYC/N-driven gene expression

(MYC_TARGETS_V1) was markedly upregulated in tumors. This was in sharp contrast to AGM

samples, indicating strong MYCN/Mycn-dependent tumor induction and progression in both, TI and

TIM. Intriguingly, strong association of hallmark NES (normalized enrichment score) values was

determined in between tumors, but not in comparison to AGM, indicating strong similarity of gene

expression in TI and TIM (Supplementary Fig. 14b). This was further evaluated for representative

genes and by GSEA of larger curated gene set collections, the human C2 and mouse M2 (Fig. 7e, f;

Supplementary Table 3). GSEA in C2 indicated up- and downregulation of gene signatures

characteristic for pediatric cancer and MYC/N-driven gene expression (Supplementary Fig. 14c). One

of the strongest upregulations in C2 was observed for the FISCHER_DREAM_TARGETS gene set, which

partially overlaps with E2F_TARGETS [71]. Despite known cross-talk of MYC/N and E2F-driven gene

expression, this supports IGF2BP1-dependent stimulation of RB-E2F-controlled cell cycle (CC) genes

and suggests additional roles of IGF2BP1 in activating DREAM-repressed CC genes. Among most

downregulated gene sets was CUI_TCF21_TARGETS_2_DN, whereas CUI_TCF21_TARGETS_2_UP was

significantly enriched. Accordingly, the expression of TCF21, a crucial developmental transcription

factor and strong tumor suppressor [72], was essentially abolished in tumors (Fig. 7e). GSEA in M2

confirmed TCF21-dependency and revealed similarities with high-grade small- (SCNEC) and large-cell

(LCNEC) neuroendocrine lung carcinoma mouse models. These where derived by combined deletion

of key tumor suppressors (Pten and Trp53) and disturbing E2F-/DREAM-repression of CC genes by

deleting Rb1 or Rbl1/Rbl2 (p107/p130) [73]. Only Rbl2 was substantially decreased in tumors,

whereas Trp53, Rb1, Rbl1 and Pten mRNA expression remained largely unchanged (Fig. 7e). The

downregulation of Rbl2, a key target of the MYC/N-driven miR-17/92 cluster [74], prompted us to test miRNA expression in TI and TIM. Consistent with upregulation of MYCN/Mycn-driven gene synthesis, the pro-tumorigenic miR-17/92 cluster was substantially upregulated in both (Fig. 7e, g). In contrast, the rather tumor suppressive let-7 miRNA family was decreased, supporting modest to strong upregulation of the let-7 miRNA suppressor Lin28b in tumors (Fig. 7e).

DISCUSSION

Our studies provide the first evidence that IGF2BP1 is a potent and druggable oncogene in neuroblastoma, with target prospects in other MYC/N-driven malignancies. In synergy with MYCN, IGF2BP1 initiates and promotes HRN by transcriptional/post-transcriptional feedforward regulation. MYCN is a versatile transcriptional driver of oncogene expression, most prominently in MNA neuroblastoma [2]. IGF2BP1 is a post-transcriptional enhancer of oncogene expression [21-24], including MYCN and BIRC5, in various cancers with exceeding expression in Chr 17q unbalanced neuroblastoma. MYCN/IGF2BP1 cross-talk results in fostered MYCN-driven transcription and IGF2BP1-directed mRNA stabilization of oncogenic effectors. Many of these, e.g. *NME1*, *PYCR1*, *TK1*, *BIRC5* and *TOP2A*, are located on Chr 17q, are upregulated in unfavorable neuroblastoma and associated with poor patient outcome [12, 18, 75-77]. Strikingly, MYCN/IGF2BP1-driven gene expression leads to increased output of oncogenic factors in a largely miRNA-dependent manner [53, 78, 79]. Most prominently, IGF2BP1 impairs the MYC/N-driven miR-17/92 cluster in down tuning MYC/N expression by negative feedback regulation [53, 74]. MYCN/IGF2BP1 feedback regulation also stimulates LIN28B expression, a strong inducer of neuroblastoma [66]. This promotes oncogenic factors like MYCN, IGF2BP1 and LIN28B by decreasing let-7 miRNA biogenesis and enhancing miRNA antagonizing roles of IGF2BP1 [22, 80]. Thus, deregulated miRNA synthesis and selective impairment of miRNA-directed downregulation of oncogene expression by IGF2BP1 are major mechanisms promoting neuroblastoma initiation and progression. IGF2BP1 furthermore stabilizes MYCN protein, apparently by enhancing E2F/DREAM-regulated genes like AURKA, PLK1 and CDK1 [24, 54, 71]. Collectively, this emphasizes the strong synergy of MYCN and IGF2BP1 in promoting HRN.

MYCN/IGF2BP1 synergy also promotes chromosomal gains at 2p and 17q, but retains strong potential also in non-amplified (2p or 17q) neuroblastoma models, e.g. NBL-S. This relies on the broad impact of MYCN/IGF2BP1-driven gene expression leading to enforced oncogene synthesis, most prominently of Chr 17q genes like *BIRC5*. In transgenic LSL-*IGF2BP1* mouse models, neuroblastoma formation was strictly IGF2BP1 dose-dependent. High incidence was only observed at elevated IGF2BP1 expression in homozygous mice. Apparently, feedforward regulation by MYCN/IGF2BP1 critically relies on IGF2BP1 to stabilize the exceeding demand of transcripts arising by MYCN-driven synthesis. Accordingly, MYCN like MYC [56] promotes IGF2BP1 synthesis culminating in an oncogene storm, which likely contributes to severe genome destabilization. This is evidenced by chromosomal misbalance reminiscent of human neuroblastoma in MYCN- as well as IGF2BP1-driven neuroblastoma mouse models [65, 81]. In support of dose dependence and IGF2BP1-directed MYCN protein stabilization, this is not seen in $R26^{MYCN}$ model, but striking in R26^{IGF2BP1}, the only model with Chr 2p/17q syntenic aberrations. This suggests that super-critical IGF2BP1 levels require a second hit, most likely *MYCN*-amplification, feeding IGF2BP1 synthesis to push feedforward regulation to a level unleashing an oncogene storm. Strong oncogenic synergy of MYCN/IGF2BP1 is evidenced in R26$^{IGF2BP1/MYCN}$ mice, showing reduced tumor latency without or mild chromosomal disturbance. A simple matter of time appears unlikely in view of genomic aberrations observed in other *MYCN*-driven neuroblastoma models within 80 d [65]. Irrespectively, R26$^{IGF2BP1/MYCN}$ and R26$^{IGF2BP1/IGF2BP1}$ neuroblastoma show strikingly similar gene expression, most prominently induction of E2F/DREAM-controlled CC genes. This strongly emphasizes the impact of MYCN/IGF2BP1 synergy in reprogramming gene expression independent of underlying genomic disturbances. IGF2BP1 fosters resistance to apoptosis by DNA-damaging drugs, e.g. YM-155 and doxorubicin [14, 55]. This may also limit spontaneous proliferation-associated apoptosis due to IGF2BP1-dependent elevation of cIAP (BIRC2), survivin (BIRC5), Wip-1 (PPM1D) and TOP2A, which promote DNA-repair and/or serve roles in chromosome stability as well as apoptosis [82-85]. Along these lines, it appears reasonable that IGF2BP1 supports MYC/N-driven proliferation capacity in embryonal neuroblasts, other

childhood/youth cancers with strong MYC/N-dependency and aberration at Chr 17q, e.g. rhabdomyosarcoma and medulloblastoma, as well as carcinomas in general.

Consistent with devastating consequences of MYCN/IGF2BP1 synergy, our studies highlight potential therapeutic prospects of IGF2BP1i. Its dose-dependent and broad oncogenic action indicates promising target potential of IGF2BP1 for pharmacological inhibition. Even if IGF2BP1i by small molecule inhibitors disrupting mRNA stabilization remains incomplete, as typically observed, it will have broad impact. IGF2BP1i likely affects many so far non-druggable effectors and directly (e.g. BIRC5) or largely indirectly (e.g. MYC/N) targetable oncogenes. This would be expected to reduce adverse effects and enhance therapeutic efficacy in combined therapies, e.g. shown here with BIRC5i and previously suggested with TOP2Ai [14]. In support of this, IGF2BP1i by BTYNB was proven beneficial in combined treatment with standard-of-care drugs for neuroblastoma treatment like Etoposide or Vincristine [55]. Moreover, BTYNB promotes the efficacy of therapies impairing E2F/DREAM-regulated CDK4/6, e.g. by Palbociclib [24], and indirect inhibition of MYCN by BRDi [58, 59]. Among a variety of BRDi, we demonstrate the best synergy of IGF2BP1i with Mivebresib. Here, we provide the first *in vivo* evidence for such benefits by revealing that BTYNB is a promising lead for developing more potent IGF2BP1i in cancer treatment. In neuroblastoma xenograft studies, BTYNB pre-treatment impaired engraftment and growth. Strikingly, i.t. BTYNB application alone reduced tumor growth without substantial side effects. However, monotherapies with i.p. application of BTYNB on PDX model resulted in less prominent efficacy probably due to high plasma protein binding and potentially poor pharmacological properties.

Conclusion

We provide the first evidence that IGF2BP1 is a potent and druggable chromosome 17q oncogene. In neuroblastoma, IGF2BP1 synergizes with MYCN by transcriptional/post-transcriptional feed-forward regulation, which unleashes an oncogene storm and genomic instability reminiscent of high-risk

diseases. Our studies unravel that impairing IGF2BP1-RNA association by the small molecules BTYNB disrupts this oncogene storm and provides benefits in combined treatment with MYC/N inhibition via BRD inhibitors, most prominently Mivebresib, as well as inhibitors of MYCN/IGF2BP1-driven oncogenes like BIRC5. Future studies need to progress the potency and pharmacological properties of IGF2BP1 inhibitors to effectively disrupt IGF2BP1-dependent oncogene enhancement. BTYNB appears a promising starting point for these endeavors. The here presented mouse models will expedite the evaluation of improved IGF2BP1i and provide valuable resources for identifying additional IGF2BP1-driven oncogenic effectors for combined cancer treatment.

Abbreviations

3′UTR: 3′ untranslated region; ADRN: adrenergic; AG: adrenal gland; AGM: adrenal gland from LSL-MYCN mouse model; AGO2: argonaute RISC catalytic component 2; AI: adrenal gland from LSL-IGF2BP1 mouse model; AIM: adrenal gland from LSL-IGF2BP1/MYCN mouse model; BIRC5: baculoviral IAP repeat containing 5; BRD: bromodomain-containing protein; BW: body weight; CC: cell cycle; ChIP: chromatin immunoprecipitation; Chr: chromosome; CN: copy number; CRISPR/Cas9: clustered regularly interspaced short palindromic repeats and CRISPR associated protein 9; DBH: dopamine beta-hydroxylase; E2F1: E2F transcription factor 1; EC_{50}: half maximal effective concentration; eCLIP: enhanced crosslinking and immunoprecipitation; EEF2: eukaryotic translation elongation factor 2; FACS: fluorescence-activated cell sorting; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GSEA: gene set enrichment analysis; hESCs: human embryonic stem cells; HIST1: histone cluster 1 H2A family member c; HIST2: histone cluster 2 H3 family member a; HPLC: high performance liquid chromatography; HR: hazard ratio; HRN: high-risk neuroblastoma; i.p.: intra-peritoneal; i.t.: intra-tumoral; iCRE: improved Cre recombinase; IGF2BP1: insulin-like growth factor 2 mRNA-binding protein 1; INSS: international neuroblastoma staging system; KO: knockout; LCNEC: high-grade large-cell neuroendocrine lung carcinoma; m^6A: N^6-methyladenosine; MES: mesenchymal; METTL14: methyltransferase 14, N^6-adenosine-methyltransferase subunit; METTL3:

methyltransferase 3, N^6-adenosine-methyltransferase complex catalytic subunit; miTRAP: miRNA trapping by RNA in vitro affinity purification; MNA: *MYCN*-amplified; MS2-BP: MS2-binding protein; mut: mutated; MYCN: v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; NES: normalized enrichment score; nMNA: non-*MYCN*-amplified; PCA: principal component analysis; PDX: patient-derived xenograft; R26: ROSA26 locus; RIP: RNA immunoprecipitation; RPLP0: ribosomal protein lateral stalk subunit P0; s.c.: subcutaneous; SCNEC: high-grade small-cell neuroendocrine lung carcinoma; sWGS: shallow whole genome sequencing; TI: tumor from LSL-IGF2BP1 mouse model; TIM: tumor from LSL-IGF2BP1/MYCN mouse model; VCL: vinculin; wt: wildtype; ZIP: zero interaction potency

Declarations

Ethical approval and consent to participate

Neuroblastoma tumors were granted after patient consent and ethical approval from the Cologne tumor bank and the Universitätsklinikum Essen, Germany. Animals were handled according to the guidelines of the Martin Luther University. Permission was granted by the state administration office of Saxony-Anhalt (reference number: 42502-2-1381 MLU, 42502-2-1530 MLU, 42502-2-1625 MLU).

Consent for publication

Not applicable.

Availability of data and materials

Presented sequencing data have been deposited in NCBI's Gene Expression Omnibus SuperSeries and are accessible through GEO accession number GSE181582 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE181582). Human DNA- and RNA-seq data are also available via the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl; datasets: "Tumor Neuroblastoma - Bell") for interactive use. Corresponding miRNA sequencing data for human neuroblastoma samples is available under GEO accession number GSE155945 or in the R2 database. Processed sequencing data for all analysis (transgenic mice, human neuroblastoma, cell lines) are available in Supplementary Table 9.

Competing interests

The authors declare that they have no competing interests.

Funding

Authors' contributions

Acknowledgements

References

1. Kushner BH: **Neuroblastoma: a disease requiring a multitude of imaging studies**. *J Nucl Med* 2004, **45**(7):1172-1188.
2. Park JR, Eggert A, Caron H: **Neuroblastoma: biology, prognosis, and treatment**. *Hematol Oncol Clin North Am* 2010, **24**(1):65-86.
3. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A *et al*: **The genetic landscape of high-risk neuroblastoma**. *Nat Genet* 2013, **45**(3):279-284.
4. Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H *et al*: **Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma**. *N Engl J Med* 1999, **340**(25):1954-1961.
5. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB: **Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response**. *Lancet Oncol* 2009, **10**(3):267-277.
6. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S *et al*: **Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci**. *J Clin Oncol* 2009, **27**(10):1627-1636.
7. Draper JS, Smith K, Gokhale P, Moore HD, Maltby E, Johnson J, Meisner L, Zwaka TP, Thomson JA, Andrews PW: **Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells**. *Nat Biotechnol* 2004, **22**(1):53-54.
8. Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD *et al*: **Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data**. *Oncogene* 2007, **26**(53):7432-7444.
9. Decaesteker B, Denecker G, Van Neste C, Dolman EM, Van Loocke W, Gartlgruber M, Nunes C, De Vloed F, Depuydt P, Verboom K *et al*: **TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets**. *Nat Commun* 2018, **9**(1):4866.
10. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J: **PPM1D is a potential target for 17q gain in neuroblastoma**. *Cancer Res* 2003, **63**(8):1876-1883.
11. Yoon KJ, Danks MK, Ragsdale ST, Valentine MB, Valentine VA: **Translocations of 17q21 approximately qter in neuroblastoma cell lines infrequently include the topoisomerase IIalpha gene**. *Cancer Genet Cytogenet* 2006, **167**(1):92-94.
12. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y *et al*: **High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma**. *Oncogene* 2000, **19**(5):617-623.
13. Nagy Z, Seneviratne JA, Kanikevich M, Chang W, Mayoh C, Venkat P, Du Y, Jiang C, Salib A, Koach J *et al*: **An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability**. *Nat Commun* 2021, **12**(1):1881.
14. Bell JL, Turlapati R, Liu T, Schulte JH, Huttelmaier S: **IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma**. *J Clin Oncol* 2015, **33**(11):1285-1293.
15. Bell JL, Hagemann S, Holien JK, Liu T, Nagy Z, Schulte JH, Misiak D, Huttelmaier S: **Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma**. *Int J Mol Sci* 2020, **21**(14).
16. Gutschner T, Hammerle M, Pazaitis N, Bley N, Fiskin E, Uckelmann H, Heim A, Grobeta M, Hofmann N, Geffers R *et al*: **Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma**. *Hepatology* 2014, **59**(5):1900-1911.
17. Stohr N, Kohn M, Lederer M, Glass M, Reinke C, Singer RH, Huttelmaier S: **IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling**. *Genes Dev* 2012, **26**(2):176-189.

18. Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL *et al*: **Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation**. *Nat Cell Biol* 2018, **20**(3):285-295.

19. Muller S, Glass M, Singh AK, Haase J, Bley N, Fuchs T, Lederer M, Dahl A, Huang H, Chen J *et al*: **IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner**. *Nucleic Acids Res* 2019, **47**(1):375-390.

20. Muller S, Bley N, Glass M, Busch B, Rousseau V, Misiak D, Fuchs T, Lederer M, Huttelmaier S: **IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors**. *Nucleic Acids Res* 2018, **46**(12):6285-6303.

21. Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M, Huttelmaier S: **Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?** *Cell Mol Life Sci* 2013, **70**(15):2657-2675.

22. Busch B, Bley N, Muller S, Glass M, Misiak D, Lederer M, Vetter M, Strauss HG, Thomssen C, Huttelmaier S: **The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family**. *Nucleic Acids Res* 2016, **44**(8):3845-3864.

23. Kobel M, Weidensdorfer D, Reinke C, Lederer M, Schmitt WD, Zeng K, Thomssen C, Hauptmann S, Huttelmaier S: **Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma**. *Oncogene* 2007, **26**(54):7584-7589.

24. Muller S, Bley N, Busch B, Glass M, Lederer M, Misiak C, Fuchs T, Wedler A, Haase J, Bertoldo JB *et al*: **The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer**. *Nucleic Acids Res* 2020, **48**(15):8576-8590.

25. Mahapatra L, Andruska N, Mao C, Le J, Shapiro DJ: **A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation**. *Transl Oncol* 2017, **10**(5):818-827.

26. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y *et al*: **Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors**. *Clin Cancer Res* 2009, **15**(11):3872-3880.

27. McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, Mantei RA, Pratt JK, Sheppard GS, Bui MH *et al*: **Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin -4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor**. *J Med Chem* 2017, **60**(20):8369-8384.

28. Kim D, Langmead B, Salzberg SL: **HISAT: a fast spliced aligner with low memory requirements**. *Nat Methods* 2015, **12**(4):357-360.

29. Langmead B, Salzberg SL: **Fast gapped-read alignment with Bowtie 2**. *Nat Methods* 2012, **9**(4):357-359.

30. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD: **The sva package for removing batch effects and other unwanted variation in high-throughput experiments**. *Bioinformatics* 2012, **28**(6):882-883.

31. Robinson MD, McCarthy DJ, Smyth GK: **edgeR: a Bioconductor package for differential expression analysis of digital gene expression data**. *Bioinformatics* 2010, **26**(1):139-140.

32. Robinson MD, Oshlack A: **A scaling normalization method for differential expression analysis of RNA-seq data**. *Genome Biol* 2010, **11**(3):R25.

33. van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J *et al*: **Neuroblastoma is composed of two super-enhancer-associated differentiation states**. *Nat Genet* 2017, **49**(8):1261-1266.

34. Durinck S, Spellman PT, Birney E, Huber W: **Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt**. *Nat Protoc* 2009, **4**(8):1184-1191.

35. Kildisiute G, Kholosy WM, Young MD, Roberts K, Elmentaite R, van Hooff SR, Pacyna CN, Khabirova E, Piapi A, Thevanesan C *et al*: **Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell**. *Sci Adv* 2021, **7**(6).

36. Gardina PJ, Lo KC, Lee W, Cowell JK, Turpaz Y: **Ploidy status and copy number aberrations in primary glioblastomas defined by integrated analysis of allelic ratios, signal ratios and loss of heterozygosity using 500K SNP Mapping Arrays**. *BMC Genomics* 2008, **9**:489.

37. Gel B, Serra E: **karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data**. *Bioinformatics* 2017, **33**(19):3088-3090.

38. Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, Dharia NV, Montgomery PG, Cowley GS, Pantel S *et al*: **Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells**. *Nat Genet* 2017, **49**(12):1779-1784.

39. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK: **limma powers differential expression analyses for RNA-sequencing and microarray studies**. *Nucleic Acids Res* 2015, **43**(7):e47.

40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES *et al*: **Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles**. *Proc Natl Acad Sci U S A* 2005, **102**(43):15545-15550.

41. Yu G, Wang LG, Han Y, He QY: **clusterProfiler: an R package for comparing biological themes among gene clusters**. *OMICS* 2012, **16**(5):284-287.

42. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP: **Molecular signatures database (MSigDB) 3.0**. *Bioinformatics* 2011, **27**(12):1739-1740.

43. Xuan JJ, Sun WJ, Lin PH, Zhou KR, Liu S, Zheng LL, Qu LH, Yang JH: **RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data**. *Nucleic Acids Res* 2018, **46**(D1):D327-D334.

44. Oki S, Ohta T, Shioi G, Hatanaka H, Ogasawara O, Okuda Y, Kawaji H, Nakaki R, Sese J, Meno C: **ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data**. *EMBO Rep* 2018, **19**(12).

45. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, Prenter S, Bray I, Watters KM, Higgins D *et al*: **Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation**. *PLoS One* 2009, **4**(12):e8154.

46. Braun J, Misiak D, Busch B, Krohn K, Huttelmaier S: **Rapid identification of regulatory microRNAs by miTRAP (miRNA trapping by RNA in vitro affinity purification)**. *Nucleic Acids Res* 2014, **42**(8):e66.

47. Ianevski A, Giri AK, Aittokallio T: **SynergyFinder 2.0: visual analytics of multi-drug combination synergies**. *Nucleic Acids Res* 2020, **48**(W1):W488-W493.

48. Bell JL, Turlapati R, Liu T, Schulte JH, Hüttelmaier S: **IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma**. *J Clin Oncol* 2015, **33**(11):1285-1293.

49. Maris JM, Matthay KK: **Molecular biology of neuroblastoma**. *J Clin Oncol* 1999, **17**(7):2264-2279.

50. Spitz R, Hero B, Ernestus K, Berthold F: **Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma**. *Clin Cancer Res* 2003, **9**(1):52-58.

51. Stallings RL, Howard J, Dunlop A, Mullarkey M, McDermott M, Breatnach F, O'Meara A: **Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?** *Cancer Genet Cytogenet* 2003, **140**(2):133-137.

52. Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E *et al*: **Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries**. *Nat Genet* 2017, **49**(9):1408-1413.

53. Misiak D, Hagemann S, Bell JL, Busch B, Lederer M, Bley N, Schulte JH, Huttelmaier S: **The MicroRNA Landscape of MYCN-Amplified Neuroblastoma**. *Front Oncol* 2021, **11**:647737.

54. Glass M, Misiak D, Bley N, Muller S, Hagemann S, Busch B, Rausch A, Huttelmaier S: **IGF2BP1, a Conserved Regulator of RNA Turnover in Cancer**. *Front Mol Biosci* 2021, **8**:632219.

55. Biegel JM, Dhamdhere M, Gao S, Gowda CP, Kawasawa YI, Spiegelman VS: **Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents**. *Front Oncol* 2021, **11**:608816.

56. Noubissi FK, Nikiforov MA, Colburn N, Spiegelman VS: **Transcriptional Regulation of CRD-BP by c-myc: Implications for c-myc Functions**. *Genes Cancer* 2010, **1**(10):1074-1082.

57. Huang M, Weiss WA: **Neuroblastoma and MYCN**. *Cold Spring Harb Perspect Med* 2013, **3**(10):a014415.

58. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P *et al*: **Targeting MYCN in neuroblastoma by BET bromodomain inhibition**. *Cancer Discov* 2013, **3**(3):308-323.

59. Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schafers S, Bell E, Nortmeyer M, Westermann F *et al*: **Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition**. *Clin Cancer Res* 2016, **22**(10):2470-2481.

60. Zimmerman MW, Liu Y, He S, Durbin AD, Abraham BJ, Easton J, Shao Y, Xu B, Zhu S, Zhang X *et al*: **MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification**. *Cancer Discov* 2018, **8**(3):320-335.

61. Huang X, Zhang H, Guo X, Zhu Z, Cai H, Kong X: **Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer**. *J Hematol Oncol* 2018, **11**(1):88.

62. Rauch A, Hennig D, Schafer C, Wirth M, Marx C, Heinzel T, Schneider G, Kramer OH: **Survivin and YM155: how faithful is the liaison?** *Biochim Biophys Acta* 2014, **1845**(2):202-220.

63. Papadopoulos KP, Lopez-Jimenez J, Smith SE, Steinberg J, Keating A, Sasse C, Jie F, Thyss A: **A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma**. *Leuk Lymphoma* 2016, **57**(8):1848-1855.

64. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P *et al*: **Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin**. *J Clin Oncol* 2008, **26**(32):5198-5203.

65. Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprussel A, Lindner S, De Preter K, Florin A, Heukamp LC *et al*: **A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies**. *Oncogene* 2015, **34**(26):3357-3368.

66. Molenaar JJ, Domingo-Fernandez R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J *et al*: **LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression**. *Nat Genet* 2012, **44**(11):1199-1206.

67. Heukamp LC, Thor T, Schramm A, De Preter K, Kumps C, De Wilde B, Odersky A, Peifer M, Lindner S, Spruessel A *et al*: **Targeted expression of mutated ALK induces neuroblastoma in transgenic mice**. *Sci Transl Med* 2012, **4**(141):141ra191.

68. Lignell A, Kerosuo L, Streichan SJ, Cai L, Bronner ME: **Identification of a neural crest stem cell niche by Spatial Genomic Analysis**. *Nat Commun* 2017, **8**(1):1830.

69. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M: **Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells**. *Oncogene* 1996, **13**(4):803-812.

70. Liu Z, Chen SS, Clarke S, Veschi V, Thiele CJ: **Targeting MYCN in Pediatric and Adult Cancers**. *Front Oncol* 2020, **10**:623679.

71. Fischer M, Grossmann P, Padi M, DeCaprio JA: **Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks**. *Nucleic Acids Res* 2016, **44**(13):6070-6086.

72. Ao X, Ding W, Zhang Y, Ding D, Liu Y: **TCF21: a critical transcription factor in health and cancer**. *J Mol Med (Berl)* 2020, **98**(8):1055-1068.

73. Lazaro S, Perez-Crespo M, Lorz C, Bernardini A, Oteo M, Enguita AB, Romero E, Hernandez P, Tomas L, Morcillo MA *et al*: **Differential development of large-cell neuroendocrine or small-**

cell lung carcinoma upon inactivation of 4 tumor suppressor genes. *Proc Natl Acad Sci U S A* 2019, **116**(44):22300-22306.

74.   Tseng AM, Mahnke AH, Salem NA, Miranda RC: **Noncoding RNA Regulatory Networks, Epigenetics, and Programming Stem Cell Renewal and Differentiation: Implications for Stem Cell Therapy**. In: *Epigenetics in Human Disease.* vol. 6: Academic Press; 2018: 20.

75.   Adam K, Lesperance J, Hunter T, Zage PE: **The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis**. *Int J Mol Sci* 2020, **21**(9).

76.   Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, Zarowiecki M, Kleftogiannis D, Smith LM, Hallsworth A *et al*: **In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis**. *Cancer Res* 2019, **79**(20):5382-5393.

77.   Chen JM, Zhou CJ, Ma XL, Guan DD, Yang LY, Yue P, Gong LP: **[Abnormality of TOP2A expression and its gene copy number variations in neuroblastic tumors]**. *Zhonghua Bing Li Xue Za Zhi* 2016, **45**(11):748-754.

78.   Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R *et al*: **MYCN regulates oncogenic MicroRNAs in neuroblastoma**. *Int J Cancer* 2008, **122**(3):699-704.

79.   Samaraweera L, Spengler BA, Ross RA: **Reciprocal antagonistic regulation of N-myc mRNA by miR17 and the neuronal-specific RNA-binding protein HuD**. *Oncol Rep* 2017, **38**(1):545-550.

80.   Viswanathan SR, Daley GQ, Gregory RI: **Selective blockade of microRNA processing by Lin28**. *Science* 2008, **320**(5872):97-100.

81.   Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A *et al*: **Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors**. *Cancer Res* 2003, **63**(17):5266-5273.

82.   Conde M, Michen S, Wiedemuth R, Klink B, Schrock E, Schackert G, Temme A: **Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells**. *BMC Cancer* 2017, **17**(1):889.

83.   Pechackova S, Burdova K, Macurek L: **WIP1 phosphatase as pharmacological target in cancer therapy**. *J Mol Med (Berl)* 2017, **95**(6):589-599.

84.   Zhang M, Liang C, Chen Q, Yan H, Xu J, Zhao H, Yuan X, Liu J, Lin S, Lu W *et al*: **Histone H2A phosphorylation recruits topoisomerase IIalpha to centromeres to safeguard genomic stability**. *EMBO J* 2020, **39**(3):e101863.

85.   Faye MD, Beug ST, Graber TE, Earl N, Xiang X, Wild B, Langlois S, Michaud J, Cowan KN, Korneluk RG *et al*: **IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1**. *Oncogene* 2015, **34**(12):1532-1541.

Figure legends

Fig. 1: Unbalanced Chromosome 17q upregulates MNA neuroblastoma essential genes and indicates adverse disease outcome. (a) Frequency (%) of DNA copy number gains (red) and losses (blue) for chromosome 1 to 22 in 100 primary human neuroblastoma samples. **(b, c)** Kaplan-Meier survival analyses by Chr 17q balance status (b, left), *MYCN* amplification status in Chr 17q unbalanced tumors (b, right) and *MYCN* amplification status (c). **(d)** Genomic distribution of 175 autosomal essential genes in MNA neuroblastoma. **(e)** Genomic location and percentage gain of essential (black and *IGF2BP1* in blue) neuroblastoma genes on Chr 17 in primary neuroblastoma (non-essential *TP53* on 17p is highlighted red). **(f)** Kaplan-Meier survival analyses by IGF2BP1 mRNA expression (best cut-off).

Fig. 2: IGF2BP1 stimulated MYCN expression is 3′UTR-, miRNA- and BTYNB-dependent. (a) Western blot (n = 6) and RT-qPCR (n = 5) analysis of MYCN expression upon IGF2BP1-KO (I1-KO) in BE(2)-C. **(b)** MYCN mRNA decay monitored by RT-qPCR in control (grey) and I1-KO (blue) BE(2)-C upon indicated time of actinomycin D (ActD) treatment (n = 3). **(c)** IGF2BP1-RIP analyses in parental BE(2)-C (n = 5). **(d)** Western blotting of miTRAP from BE(2)-C lysates using MS2-fused MYCN 3′UTR or MS2-RNA (n = 1). **(e)** BTYNB-response curve in BE(2)-C (n = 3). **(f)** IGF2BP1-RIP in BE(2)-C treated with DMSO or BTYNB (n = 3). **(g)** Western blot analysis of MYCN expression in BE(2)-C treated with BTYNB (BTY, n = 3) for 3 and 6 d or replacement of BTY by DMSO after 3 d treatment. Treatment scheme in lower panel. **(h)** AGO2-RIP analyses in I1-KO versus control BE(2)-C (n = 3). **(i)** Scheme of luciferase reporters constructs. **(j)** Expression of miRNAs in BE(2)-C (left) and mutated fraction of MYCN-targeting miRNA-binding sites (right). **(k, l)** Activity of indicated luciferase reporters in control and I1-KO (k, n = 5) or DMSO- and BTYNB-treated BE(2)-C (l, n = 3).

Fig. 3: IGF2BP1 deletion and inhibition by BTNYB impairs xenograft tumor growth. (a, b) The viability and caspase3/7-activity of parental (Ctrl) and I1-KO BE(2)-C was analyzed in spheroid growth (a, n = 3) and anoikis-resistance studies (b, n = 4; bars a, 200 µm and b, 400 µm). **(c-e)** Tumor growth (n = 6) of Ctrl and I1-KO BE(2)-C s.c. xenografts was monitored by non-invasive infrared imaging (c),

tumor-free survival (d) and final tumor mass (e). **(f)** RT-qPCR analysis of MYCN mRNA levels in excised xenograft tumors and non-palpable tumor cell mass upon I1-KO (Ctrl, n = 5; I1-KO, n = 2). **(g, h)** Tumor growth (n = 6) of Ctrl and I1-KO (g) or DMSO- and BTYNB-pretreated (h) BE(2)-C xenografts was monitored by tumor volume over time. **(i)** Tumor growth (n = 6) was monitored by relative volume of s.c. PDX tumors treated i.p. with DMSO (grey) or BTYNB (blue). Daily treatment in three cycles is indicated by dashed lines below the x-axis. **(j)** Tumor growth (n = 9) was monitored by relative volume of s.c. BE(2)-C treated i.t. with DMSO (grey) or 50 mg/kg BW BTYNB (blue). Daily treatment in two cycles is indicated by dashed lines below the x-axis. **(k)** Representative images of tumors at start (day 0) and final treatment (day 8).

Fig. 4: MYCN-driven IGF2BP1 expression is impaired by BRD inhibitors. (a) MYCN ChIP-seq profile of the *IGF2BP1* promoter region. E-Boxes, putative MYC/N-binding sites, are indicated in dark blue. The *IGF2BP1* gene is depicted schematically in orange up to the beginning of the second intron. **(b)** Western blot (n = 3) and RT-qPCR (n = 6) analysis of IGF2BP1 expression upon MYCN (siMN) compared to control knockdown (siC) in BE(2)-C. **(c)** RT-qPCR (n = 3) analysis of indicated nascent mRNAs upon MYCN compared to control knockdown in BE(2)-C (I1 - IGF2BP1). **(d)** Scheme of putative MYCN regulation by BRD (TF - transcription factor). **(e)** Western blot and RT-qPCR analysis of MYCN and IGF2BP1 expression upon treatment of BE(2)-C with indicated BRD inhibitors (n = 3). **(f)** Mivebresib response curve in control (black) and I1-KO (red) BE(2)-C (n = 4). **(g)** Relief plot depicting the ZIP synergy for combined treatment of BTYNB and Mivebresib in BE(2)-C (n = 3).

Fig. 5: MYCN/IGF2BP1 feedforward regulation promotes expression of druggable oncogenes located on Chr 17q. (a) Western blot analysis of BIRC5 expression upon MYCN (siMN) or IGF2BP1 (siI1) compared to control (siC) knockdown in BE(2)-C (n = 3). **(b)** MYCN ChIP-seq profile of the *BIRC5* promoter region (upper panel) and IGF2BP1-CLIP profile for the BIRC5 mRNA (lower panel). **(c)** BIRC5 3´UTR luciferase activity in I1-KO versus parental (Ctrl) and BTYNB- versus DMSO-treated BE(2)-C (n = 3). **(d)** YM-155 response curve in control (black) and I1-KO (red) BE(2)-C (n = 4). **(e)** Tumor growth (n = 6) was monitored by relative volume of s.c. PDX tumors treated i.p. with DMSO (grey), YM-155

(orange) or in combination of YM-155 and BTYNB (red). Daily treatment in three cycles is indicated by dashed lines below the x-axis. **(f)** Relief plot showing the ZIP synergy for combined treatment of BTYNB and YM-155 in KELLY (n = 3). **(g)** Scheme of transcriptional/post-transcriptional feedback regulation of MYC/N, IGF2BP1 and downstream effectors as well as treatment possibilities.

Fig. 6: IGF2BP1 induces neuroblastoma, Mycn expression, stabilizes MYCN protein and synergizes with MYCN in transgenic mice. (a) Kaplan-Meier survival analysis of heterozygous (cyan, n = 8) and homozygous (blue, n = 7) R26^{IGF2BP1}, heterozygous R26^{MYCN} (black, n = 6) and double transgenic R26$^{IGF2BP1/MYCN}$ (red, n = 8) mice. Numbers in brackets indicate tumor bearing mice. **(b)** Scheme of tumor location within mice. **(c)** Representative images of hematoxylin and eosin staining (HE, top) and Phox2b immunohistochemistry (bottom) indicative for neuroblastoma in R26$^{IGF2BP1/IGF2BP1}$ mice (bars: 40 μm). **(d)** PCA of mouse adrenal glands and transgenic tumors. **(e)** Ratio of ADRN to MES signature of mouse adrenal glands and transgenic tumors. **(f)** Heatmap depicting row-scaled FPKM values of indicated murine mRNAs in adrenal glands derived from wildtype (n = 3, AG) or R26$^{MYCN/-}$ (n = 5, AGM) mice and tumors of R26^{IGF2BP1} (n = 8, TI) or R26$^{IGF2BP1/MYCN}$ (n = 8, TIM) mice. **(g)** Western blot analysis confirms IGF2BP1 or MYCN transgene expression in tumors and adrenal glands of representative mice (n = 1). **(h)** RT-qPCR analysis of human IGF2BP1 and MYCN mRNA in indicated mouse tissue (n. d. - not determined). **(i)** Scheme of MYCN protein regulation. **(j)** Western blot (n = 5) analysis of MYCN expression upon IGF2BP1 (siI1) compared to control (siC) knockdown in TET21N cells. **(k)** MYCN protein decay was monitored by Western Blot analysis in control (grey) and IGF2BP1 knockdown (blue) TET21N cells upon indicated time of emetin treatment (n = 3). **(l, m)** RNA-seq analysis of indicated mRNAs in mouse tissues (l) or upon transient IGF2BP1 knockdown in BE(2)-C and KELLY (m). **(n)** Western blot (n = 3) analysis of indicated proteins upon IGF2BP1 (siI1) compared to control (siC) knockdown in BE(2)-C.

Fig. 7: IGF2BP1-induced murine neuroblastoma comprises syntenic chromosomal aberrations and gene expression profiles observed in human high-risk disease. (a-c) Frequency (%) of DNA copy number gains (red) and losses (blue) for murine chromosome 1 to 19 in R26$^{IGF2BP1/MYCN}$ (a) or R26^{IGF2BP1}

(b) tumors compared to wildtype adrenal glands and lift over of R26^{IGF2BP1} regions to the human genome (c, Chr 1-22). Overlay of human neuroblastoma sWGS is depicted in transparent colors (c). (d) Selected hallmark gene sets in R26^{IGF2BP1} (TI), R26$^{IGF2BP1/MYCN}$ (TIM) or R26^{MYCN} (AGM) mice based on GSEA. (e) RNA-seq analysis of indicated mRNAs presented as log$_2$ fold change (log$_2$FC) compared to wildtype adrenal glands. (f) Correlation of NES values of C2 (left) and M2 (right) gene sets between TI and TIM. Non-significant gene sets are depicted in grey. (g) Log$_2$FC of miRNAs from the miR-17-92 cluster and let-7 family between R26^{IGF2BP1} or R26$^{IGF2BP1/MYCN}$ tumors and normal adrenal gland tissue. SCNEC/LCNEC - genetic mouse model high-grade small/large-cell neuroendocrine lung carcinoma

Supplementary information

Additional file 1 Supplementary Fig. 1: IGF2BP1 and MYCN upregulation synergize in high-risk neuroblastoma. (a-h) Kaplan-Meier survival analyses by indicated conditions (best cut-off). **(i)** Spearman correlation of IGF2BP1 and MYCN mRNA expression in neuroblastoma tumors. MNA samples are color-coded in red. **(j-m)** IGF2BP1 mRNA expression separated by *MYCN* status (j), Chr 17 balance status (k), INSS stage (l) and survival (m). **(n)** Correlation analysis of Spearman correlation coefficients determined for IGF2BP1- and MYCN-associated gene expression in primary tumors. **(o)** Spearman correlation analysis of the logFC of mRNAs after IGF2BP1- or MYCN-knockdown in BE(2)-C. **(p)** Expression of IGF2BP1 (middle) and MYCN (right) in neuroblastoma upon single cell sequencing. Cell types are indicated in the left panel. **(q)** Correlation analysis of single cell sequencing data of IGF2BP1 and MYCN (left) or ACTB (right). nMNA - MYCN non-amplified, MNA - MYCN-amplified, bal - balanced Chr 17, unbal - unbalanced Chr 17

Additional file 2 Supplementary Fig. 2: IGF2BP1-driven and BTYNB-druggable MYCN expression is conserved in NBL-S and KELLY neuroblastoma cells. (a) IGF2BP1-CLIP hits in the MYCN mRNA derived from two studies in hESC. **(b)** Western blot and RT-qPCR analyses of MYCN expression upon I1-KO in NBL-S and KELLY (n = 3). **(c)** IGF2BP1-RIP analyses in NBL-S and KELLY (n = 3). **(d)** BTYNB- response curves in NBL-S and KELLY (n = 3). **(e)** Western blot analysis of MYCN expression upon treatment of NBL-S and KELLY with BTYNB (n = 3). **(f-h)** Relative activity of MYCN 3´UTR luciferase

reporter in NBL-S and KELLY determined between I1-KO and control cells (f), mutant and wildtype MYCN 3′UTR (g) or BTYNB- and DMSO-treated cells (h; all n = 3).

Additional file 3 Supplementary Fig. 3: Validation of IGF2BP1 and AGO2 immunoprecipitation. (a-c)

Isolation of indicated proteins (IGF2BP1, AGO2) in RIP studies from parental BE(2)-C, NBL-S and KELLY (a), DMSO- and BTYNB-treated BE(2)-C (b) or parental (Ctrl) and I1-KO (c) cells was analyzed by Western blotting (a, n = 5; b and c, n = 3). BC - bead control

Additional file 4 Supplementary Fig. 4: Regulation of MYCN by IGF2BP1 is largely m⁶A-independent.

(a) N^6-Methyladenosine (m⁶A) modification profile of MYCN mRNA. **(b, c)** Western blot (b; BE(2)-C, n = 3; KELLY, n = 4) and RT-qPCR (c; n = 3) analyses of MYCN expression upon co-depletion of the key mRNA m⁶A-methyltransferase complex METTL3/14 (siM3/14) compared to control knockdown (siC). **(d)** RNA-seq data of E2F1 expression in BE(2)-C and KELLY upon transient control (siC) and IGF2BP1 (siI1) knockdown (n = 3). B - BE(2)-C, K - KELLY

Additional file 5 Supplementary Fig. 5: Oncogenic potential of IGF2BP1 is conserved in nMNA neuroblastoma cell and xenograft model. (a, b) The viability and caspase3/7 activity of parental (Ctrl) and I1-KO NBL-S was analyzed in spheroid growth (a; n = 3) and anoikis resistance studies (b; n = 3; bars a, 200 μm; b, 400 μm). **(c-e)** Tumor growth (n = 6) of Ctrl and I1-KO NBL-S s.c. xenografts was monitored by non-invasive infrared imaging (c), tumor-free survival (d), and final tumor mass (e). **(f)** RT-qPCR analysis of MYCN mRNA levels in excised parental xenograft tumors (n = 6) and residual non-palpable I1-KO tumors (n = 5).

Additional file 6 Supplementary Fig. 6: BTYNB is stable, has minimal effect on mouse body weight, but high serum protein binding capacity. (a, b) Body weight analysis of (a, n = 6; b, n = 9) mice with s.c. PDX (a) or BE(2)-C xenograft tumors (b) treated i.p. (a) or i.t. (b) with DMSO (grey) or BTYNB (blue). Treatment cycles are indicated by dashed lines below the x-axis. **(c)** Waterfall plot showing the percentage difference in tumor size from treatment day 0 to day 8 in BE(2)-C xenograft mice treated i.t. with DMSO (beige) or BTYNB (blue; n = 9). **(d)** Final relative tumor volume of s.c. BE(2)-C

xenografts tumors treated with DMSO or BTYNB (n = 9). **(e-h)** Superimposed HPLC chromatograms for BTYNB stability in DMEM (e), under acidic conditions (f) and after incubation with FBS (g) or HSA (h) at different time points.

Additional file 7 Supplementary Fig. 7: MYCN-driven and BRDi-directed inhibition of IGF2BP1 synthesis is conserved in neuroblastoma cell models. (a) Western blot (n = 3) and RT-qPCR (n = 6) analysis of IGF2BP1 expression upon MYCN (siMN) compared to control knockdown (siC) in KELLY. **(b)** BRD inhibitor response curve in BE(2)-C, KELLY and NBL-S (n = 4). **(c)** Western blot (KELLY, n = 3; NBL-S, n = 4) and RT-qPCR (n = 3) analysis of MYCN and IGF2BP1 expression after treatment of KELLY or NBL-S with indicated BRD inhibitors. **(d)** BE(2)-C cell viability upon treatment with optimal synergy concentrations (750 nM BTYNB, 10 nM Mivebresib) alone or in combination. BTY - BTYNB, Mive - Mivebresib. **(e, f)** Relief plot showing the ZIP synergy for combined treatment of BTYNB and Mivebresib in KELLY (e) and NBL-S (f; n = 3).

Additional file 8 Supplementary Fig. 8: MYCN/IGF2BP1-driven upregulation of BIRC5 is conserved in neuroblastoma models and primary human disease. (a) Heatmap representing the identification of potential IGF2BP1 and MYCN downstream targets. Neuroblastoma and common essential genes located on Chr 17q were analyzed as described (for details refer to the online method section). Data of each row were scaled to range 0 and 1 (ChIP and CLIP) or -1 and 1 (all other). **(b)** Kaplan-Meier survival analysis of human neuroblastoma by BIRC5 expression (median cut-off). **(c, d)** Spearman correlation analyses of BIRC5 with MYCN (c) or IGF2BP1 (d) mRNA expression in human neuroblastoma tumor samples. **(e-g)** Expression of BIRC5 in neuroblastoma separated by MYCN status (e), Chr 17 balance status (f) and INSS tumor stage (g). **(h)** Western blot analysis of BIRC5 expression upon transient MYCN (siMN) or IGF2BP1 (siI1) compared to control (siC) knockdown in KELLY (n = 5). **(i)** BIRC5 3'UTR reporter activity in I1-KO versus Ctrl and BTYNB- versus DMSO-treated KELLY (n = 3). **(j)** Relief plot showing the ZIP synergy for combined treatment of BTYNB and YM-155 in BE(2)-C (n = 3). nMNA - MYCN non-amplified, MNA - MYCN-amplified, bal - balanced Chr 17, unbal - unbalanced Chr 17, TS - tumor suppressor

Additional file 9 Supplementary Fig. 9: Expression of transgenic tumors is largely location-independent. (a) Schematic overview of the LSL-transgene expression of IGF2BP1 and iRFP or MYCN and luciferase respectively from the *Rosa26* locus. Location of primers used for genotyping (A1, A2, A3, I1, I2, M1, M2) are indicated. Splice acceptor site (SA), neomycin resistance (5´del NeoR), the synthetic promoter (CAG), transcriptional stop cassette made of the human growth hormone polyadenylation signal (hGHpA), transgene open reading frame (blue), internal ribosomal entry site (IRES), iRFP or luciferase open reading frame (red), polyadenylation signal (pA). **(b)** Representative genotyping PCR validating the transgene knockin (top, primers A2 and A3) and the wildtype *Rosa26* locus (bottom, primers A1 and A3) in heterozygous (+/-), homozygous (+/+) and wildtype (wt) mice. **(c)** PCA of all sequenced adrenal glands and tumors split by their location. AG - wildtype adrenal gland, AGM - adrenal gland from R26^{MYCN}, TI - tumor from R26^{IGF2BP1}, TIM - tumor from R26$^{IGF2BP1/MYCN}$

Additional file 10 Supplementary Fig. 10: Summary and validation of analyzed R26^{IGF2BP1} tumors. (a) For each analyzed LSL-*IGF2BP1* mouse with obvious signs of tumor burden, expression of IGF2BP1/Igf2bp1, Mycn and Birc5 was validated by Western blotting (left panels, n = 1). Time until termination criteria is reached are indicated in brackets. Mouse 1-6 and 8 had abdominal tumors, whereas mouse 7 had an adrenal gland tumor. HE staining was performed on excised tumors and representative images are shown in right panels (bars 200 μm). **(b)** Genotyping PCR performed as in Supplementary Figure 10 validated *IGF2BP1* transgene (LSL-*IGF2BP1*), *Rosa26* wildtype locus (*Rosa26* wt) and *Dbh*-iCRE. K - kidney, AG - adrenal gland, T - tumor, AG T - adrenal gland tumor

Additional file 11 Supplementary Fig. 11: Summary and validation of analyzed R26$^{IGF2BP1/MYCN}$ tumors. (a) For each analyzed LSL-*IGF2BP1/MYCN* mouse with obvious signs of tumor burden, expression of IGF2BP1/Igf2bp1, MYCN/Mycn and Birc5 was validated by Western blotting (n = 1). Time until termination criteria is reached are indicated in brackets. **(b)** Genotyping PCR performed as in Supplementary Figure 10 validated *IGF2BP1* and *MYCN* transgene (LSL-*IGF2BP1*, LSL-*MYCN*), absence of *Rosa26* wildtype locus (*Rosa26* wt) and *Dbh*-iCRE. K - kidney, AG - adrenal gland, T - tumor, AG T - adrenal gland tumor, T S - tumor along spine, C - control wildtype mouse

Additional file 12 Supplementary Fig. 12: Summary and validation of analyzed R26^{MYCN} adrenal glands. (a) For each analyzed LSL-*MYCN* mouse expression of Igf2bp1, MYCN/Mycn and Birc5 was validated by Western blotting (n = 1). Each mice were culled after 365 days. As control (C) served an adrenal gland from a R26$^{IGF2BP1/MYCN}$ mouse. **(b)** Genotyping PCR validated *MYCN* transgene (LSL-*MYCN*), *Rosa26* wildtype locus (*Rosa26* wt) and *Dbh*-iCRE.

Additional file 13 Supplementary Fig. 13: IGF2BP1 influences MYCN protein turnover. (a) Western blot (n = 3) analysis of MYCN protein decay upon transient IGF2BP1 (siIGF2BP1) or control (siC) knockdown in TET21N. Treatment time with emetin in minutes are indicated. **(b)** Western blot (n = 3) analysis of indicated phosphoproteins upon IGF2BP1 (siI1) compared to control (siC) knockdown in BE(2)-C. Relative changes of phosphorylation signals to total protein level are indicated.

Additional file 14 Supplementary Fig. 14: Genomic aberration are nearly absent in R26^{MYCN} adrenal glands. (a) Frequency (%) of DNA copy number gains (red) and losses (blue) for murine chromosome 1 to 19 in R26^{MYCN} compared to wildtype adrenal glands. **(b)** Correlation of NES values of hallmark gene sets between TI and TIM (left) as well as tumors and AGM (middle, right). Non-significant gene sets are depicted in grey. **(c)** Selected gene sets from curated human (C2) and mouse (M2) collection in R26^{IGF2BP1} (TI), R26$^{IGF2BP1/MYCN}$ (TIM) or R26^{MYCN} (AGM) mice based on GSEA.

Additional file 15 Supplementary Table 1: ADRN/MES neuroblastoma signature.

Additional file 16 Supplementary Table 2: MNA neuroblastoma essential genes and respective dependency score.

Additional file 17 Supplementary Table 3: Gene set enrichment analyses of transgenic mouse tissue/tumors.

Additional file 18 Supplementary Table 4: IGF2BP1 CLIP score for protein-coding genes.

Additional file 19 Supplementary Table 5: MYCN ChIP data for protein-coding genes.

Additional file 20 Supplementary Table 6: Antibodies, primers, plasmids and siRNAs used in this study.

Additional file 21 Supplementary Table 7: Overview of transgenic mice.

Additional file 22 Supplementary Table 8: Overview of the human neuroblastoma cohort.

Additional file 23 Supplementary Table 9: Processed RNA-seq data of human and mouse samples.

a

VCL
IGF2BP1
MYCN

Ctrl   I1-KO

protein: 0.61±0.12
RNA: 0.53±0.05

b

MYCN mRNA decay

log_2 MYCN mRNA

p = 0.02

$t_{1/2}$ Ctrl = 63 min
$t_{1/2}$ I1-KO = 44 min

ActD [h]

c

IGF2BP1 RIP

mRNA enrichment

p = 2.58e-4
p = 0.032

HIST2   E2F1   MYCN

d

input   MS2   3´UTR

VCL
IGF2BP1
MS2-BP

e

BTYNB response curve

relative cell viability

EC_{50} = 3.3 µM

BTYNB [µM]

f

IGF2BP1 RIP

mRNA enrichment
(BTYNB / DMSO)

p = 0.019
p = 0.005

HIST2   E2F1   MYCN

g

DMSO BTY DMSO BTY BTY 3d+
3d   3d   6d   6d   DMSO 3d

VCL
IGF2BP1
MYCN

0.45±0.04   0.28±0.08 0.51±0.18

DMSO → 3d → DMSO → DMSO → 6d
BTYNB → 3d → DMSO → 6d
                BTYNB → 6d

h

AGO2 RIP

mRNA enrichment
(I1-KO / Ctrl)

p = 0.039

HIST2   MYCN

i

RL — FFL   MYCN 3´UTR wt
RL — FFL   MYCN 3´UTR mut

j

BE(2)-C

miRNA CPM [%]

MYCN non-targeting
MYCN poorly predicted
MYCN strongly predicted
MYCN validated
unknown
mutated
not mutated

k

Luciferase I1-KO

LUC activity

p = 1.49e-6
p = 1.21e-5
p = 1.57e-4
p = 0.565

control	+	-	-	-	-
MYCN wt	-	+	+	-	-
MYCN mut	-	-	-	+	+
Ctrl	-	+	-	+	-
I1-KO	-	-	+	-	+

l

Luciferase BTYNB

LUC activity

p = 3.65e-4
p = 0.010
p = 0.014
p = 0.311

control	+	-	-	-	-
MYCN wt	-	+	+	-	-
MYCN mut	-	-	-	+	+
DMSO	-	+	-	+	-
BTYNB	-	-	+	-	+

a spheroid growth

b anoikis resistance

c

a

MYCN ChIP

E-Box — IGF2BP1 gene

b

	siC	siMN
VCL		
MYCN		
IGF2BP1		

protein: 0.53±0.10
RNA: 0.59±0.05

c nascent RNA

nascent RNA (siMYCN / siC)

p = 0.004   p = 0.022

MYCN   I1   EEF2

d

TF → MYC/N transcription

BRDi

e

	DMSO	Mive-bresib	ARV-771	CPI-0610	INCB-057643
EC_{50}:		272 nM	4.56 µM	1.06 µM	3.64 µM
VCL					
MYCN					
protein:		0.24±0.08	0.18±0.07	0.62±0.29	0.32±0.11
RNA:		0.41±0.02	0.24±0.02	0.54±0.08	0.42±0.03
IGF2BP1					
protein:		0.55±0.05	0.68±0.06	0.54±0.05	0.53±0.06
RNA:		0.18±0.02	0.23±0.06	0.33±0.06	0.25±0.04

f Mivebresib response curve

relative cell viability

EC_{50} (Ctrl) = 272 nM
EC_{50} (I1-KO) = 42.1 nM

Mivebresib [µM]

g BE(2)-C maximum ZIP
synergy score: 19.09±4.95

δ − score

Mivebresib [µM]

BTYNB [µM]

a

	siMN	siC	siI1
VCL			
MYCN			
IGF2BP1			
BIRC5			

0.40±0.07   0.75±0.04

b

MYCN ChIP

E-Box   BIRC5 gene

IGF2BP1 CLIP sites

3´UTR

BIRC5

c BIRC5 3´UTR

LUC activity (BIRC5 3´UTR / control 3´UTR)

p = 0.020   p = 0.020

MCS   I1-KO   BTYNB

d YM-155 response curve

relative cell viability

EC$_{50}$ (Ctrl) = 206 nM
EC$_{50}$ (I1-KO) = 73.7 nM

YM-155 [µM]

e PDX: intra-peritoneal treatment

relative tumor volume

- DMSO (n = 6)
- BTYNB (n = 6)
- YM-155 (n = 6)
- BTYNB+YM-155 (n = 6)

days post treatment start

f

KELLY maximum ZIP
synergy score: 9.01±5.28

YM-155 [nM]

BTYNB [µM]

δ – score

g

miRNAs   BTYNB   YM-155

MYC/N   IGF2BP1   (A)$_n$ $_n$(A)   IGF2BP1   BIRC5

MYC/N   IGF2BP1 transcription   BIRC5 transcription   MYC/N

BRDi   Chromosome 17q   BRDi